

PROGRAMME

DGI-DZIF Joint Annual Meeting

German Society of Infectious Diseases (DGI)
German Center for Infection Research (DZIF)

1 – 3 June 2022
Maritim Hotel, Stuttgart

Face-to-face event

www.dgi-dzif-joint-meeting.de





Imprint

Responsible for editorial content:

German Society of Infectious Diseases e.V. (DGI)
Nürnberger Str. 16 · 10789 Berlin

German Center for Infection Research e.V. (DZIF)
Inhoffenstr. 7 · 38124 Braunschweig

Design & Layout

COCS media GmbH
Tal 12 · 80331 Munich
www.cocs-media.de

COCS media GmbH does not guarantee the correctness of the information.



Dear colleagues,

Due to the COVID-19 pandemic, we had to postpone our Annual Meeting last year.

We are now privileged to cordially invite you to the joint DGI/DZIF Annual Meeting in Stuttgart 1 – 3 June 2022!

The structure of this year's scientific sessions will be provided by our four grand challenges of infection research:

- Tropical and Emerging Infections
- Chronic Infections
- Immune Prevention and Therapy
- Antimicrobial Resistance

We hope to highlight existing parallels and stimulate further synergy and interactions. In the successive poster sessions, each of these grand challenge areas will present itself to the conference participants, requesting feedback and exchange.

We are looking forward to welcome you to Stuttgart.

Best regards

Your Conference Chairs

Prof. Dr.
Ayola Akim Adegnika

Prof. Dr.
Heike Brötz-Oesterhelt

Prof. Dr.
Peter Kremsner

Prof. Dr. Dr. h.c.
Christoph Lange

Prof. Dr.
Clara Lehmann

Prof. Dr.
Andreas Peschel



Conference Chairs & Organizations

Deutsches Zentrum für Infektionsforschung e.V. (DZIF)
Inhoffenstr. 7 · 38124 Braunschweig · www.dzif.de

Prof. Dr. Ayola Akim Adegnika
Internal Medicine VII – Institut for Tropical Medicine, Travel Medicine, Human Parasitology
University of Tuebingen

Prof. Dr. Heike Brötz-Oesterhelt
Microbial Bioactive Compounds
Interfaculty Institute for Microbiology and Infection Medicine
University of Tuebingen

Prof. Dr. Peter Kremsner
Internal Medicine VII – Institut for Tropical Medicine, Travel Medicine, Human Parasitology
University of Tuebingen

Prof. Dr. Andreas Peschel
Interfaculty Institute of Microbiology and Infection Medicine
Infection Biology Department
University of Tuebingen

Deutsche Gesellschaft für Infektiologie e.V. (DGI)
Nürnberger Str. 16 · 10789 Berlin · www.dgi-net.de

Prof. Dr. Dr. h.c. Christoph Lange
Medical Director, Research Center Borstel, Leibniz Lung Center
Professor of Respiratory Medicine & International Health
University of Lübeck

Prof. Dr. Clara Lehmann
Head of Infection Control Centre
Infection Outpatient Clinic & Post-COVID Outpatient Clinic
Internal Medicine I – University of Cologne

Wednesday, 1 June 2022

09.30 – 10.00	**Welcome Coffee**	
10.00 – 10.15	**Congress Opening**	Main Hall
10.15 – 12.15	**Symposium I** Immune Prevention and Therapy	Main Hall
12.15 – 14.15	**Lunch Break &** **Industrial Exhibition & Poster Session**	Room Maritim
13.15 – 14.15	**Poster Session I** Immune Prevention and Therapy	Room Maritim
14.15 – 16.15	**Symposium II** Chronic Infections	Main Hall
16.15 – 17.15	**Poster Session II** Chronic Infections	Room Maritim
from 19.00	**Get-together & Classic Concert**	Main Hall

Thursday, 2 June 2022

09.00 – 11.00	**Symposium III** Tropical and Emerging Infections	Main Hall
11.00 – 11.30	**Coffee Break & Industrial Exhibition**	Room Maritim
11.30 – 12.30	**DZIF Award Lectures**	Main Hall
12.30 – 12.45	**Group Photo**	
12.45 – 14.45	**Lunch Break & Industrial Exhibition & Poster Session**	
13.45 – 14.45	**Poster Session III** Tropical and Emerging Infections	Room Maritim
14.45 – 16.45	**Symposium IV** Antimicrobial Resistance	Main Hall
16.45 – 17.45	**Poster Session IV** Antimicrobial Resistance	Room Maritim
from 18.00	**Get-together with Jazz & DGI/DZIF Awards**	Main Hall

12.45 - 14.15
DNDi Symposium/ Salon Hamburg
TI BBD Workshop Salon Bonn

13.15 - 14.15
MSD Symposium Main Hall



Friday, 3 June 2022

09.00 – 11.00	**Symposium V** COVID I	Main Hall
11.00 – 11.30	**Coffee Break & Industrial Exhibition**	Room Maritim
11.30 – 13.30	**Symposium VI** COVID II	Main Hall
from 13.30	**Closing Remarks**	

ST = Short Talk, AT = Academy Talk

10.00 – 10.15 Main Hall	**Welcome & Congress Opening** *C. Lehmann, Cologne* *P. Kremsner, Tuebingen*
10.15 – 12.15 Main Hall	**Symposium I: Immune Prevention and Therapy** *Chairs: B. Salzberger, Regensburg* *C. Rooney, Houston/TX/USA*
10.15 – 10.30	**Overview – Immune Prevention and Therapy** *D. Busch, Munich*
10.30 – 10.45	**Covid year in review** *L.E. Sander, Berlin*
10.45 – 11.15	**Monoclonal antibodies to prevent and treat infectious diseases** *F. Klein, Cologne*
11.15 – 11.30 ST 1	**Identification of broadly neutralizing human monoclonal antibodies targeting the SARS-CoV-2 spike protein** *S. C. Stein[1], G. Ssebyatika[2], L. Ströh[1], S. Menz[1], J.-Y. Waldmann[1], S. N. Tipp[1], O. Ochulor[1], E. Herold[2], B. Schwarzloh[2], D. Mutschall[2], G. Hansen[2], J. Zischke[1], A. Cordes[1], W. Puppe[1], R. Blasczyk[3], H. Kleine-Weber[4], M. Hoffmann[4], M. M. Hoeper[5], F. K. Kaiser[6], M. Gonzalez-Hernandez[6], A. Osterhaus[6], S. Pöhlmann[4], T. F. Schulz[1], T. Krey[2]* *[1, 3, 5, 6] Hannover, [2] Lübeck, [4] Göttingen)*
11.30 – 11.45 ST 2	**MVA-MERS-S vaccine candidate induces neutralizing antibodies and long-lasting B cell memory** *M. Zehner[1], C. Kreer[1], S. Detmer[1], A. Fathi[2, 3, 4], M. Klüver[5, 6], C. Rohde[5, 6], J. Heidpriem[7], M. S. Ercanoglu[1], L. Gieselmann[1], M. Hoffmann[8, 9], A. Ashurov[1], M. Madler[1], A. M. Wunsch[1], M. Korenkov[1], C. Dahlke[2, 3, 4], M. Koch[10], S. Pöhlmann[8, 9], S. Becker[5, 6], F. Löffler[7], M. Addo[2, 3, 4], MVA-MERS-S-Study Group, F. Klein[1, 11]* *[1, 10, 11] Cologne, [2, 3, 4] Hamburg, [5, 6] Marburg, [7] Potsdam, [8, 9] Göttingen*
11.45 – 12.00 ST 3	**Development of patient-derived PcrV antibodies targeting Pseudomonas aeruginosa** *A. Simonis[1], J. Wilms[1], C. Kreer[2], M. Meyer[3], H. Gruell[2], K. Schmitt[1], M. Rieckher[4], S. J. Theobald[1], M. S. Ercanoglu[2], M. Zehner[2], S. Winter[1], E. van Gumpel[1], B. Schumacher[4], H. Seifert[5], M. Hallek[1], G. Fätkenheuer[1], E. Rietschel[3], S. van Koningsbruggen-Rietschel[3], F. Klein[2], J. Rybniker[1]* *[1, 2, 3, 4, 5] Cologne*
12.00 – 12.15 AT 1	**Depletion of granulocytic myeloid derived suppressor cells (G-MDSC) worsens the outcome of neonatal E.coli sepsis in mice** *J. Schwarz, S. Dietz, N. Köstlin-Gille, J. Rühle, C. Poets, C. Gille* *Tübingen*
12.15 – 14.15 Room Maritim	**Lunch Break and Industrial Exhibition and Poster Session**



13.15 – 14.15 Room Maritim	**Poster Session I** **Immune Prevention and Therapy** For further information please see page 18
14.15 – 16.15 Main Hall	**Symposium II: Chronic Infections** *Chairs: C. Lehmann, Cologne* *K. Klumpp, Sunnyvale/CA/USA*
14.15 – 14.30	**Overview – Chronic Infections** *M. Dandri, Hamburg*
14.30 – 14.45	**HIV year in review** *J. Rockstroh, Bonn*
14.45 – 15.15	**Drug-resistant tuberculosis** *M.P. Grobusch, Amsterdam/Netherlands*
15.15 – 15.30 ST 4	**Identification of potent HCMV trimer and pentamer specific neutralizing antibodies** *M. Zehner[1], M. Alt[2], A. Ashurov[1], K. Laib Sampaio[3], R. Spies[3], N. Weiler[3], D. Stöhr[3], C. Stegmann[4], M. S. Ercanoglu[1], L. Gieselmann[1], C. Kreer[1], R. Lotfi[5, 6], B. J. Ryckman[4, 7, 8, 9], A. Krawczyk[2], C. Sinzger[3], F. Klein[1, 10]* *[1, 10] Cologne, [2] Essen, [3, 5, 6] Ulm, [4, 7, 8, 9] Montana (United States)*
15.30 – 15.45 ST 5	**Single Cell RNA Sequencing Reveals Forced Transcriptional Modulation and Impaired Immunity upon HIV-1 Reactivation in CD4+ T-cells** *J. Kazmierski, D. Postmus, E. Wyler, C. Fischer, J. Jansen, K. Meixenberger, S. N. Vitcetz, M. Sohn, L. Loyal, A. Thiel, S. Sauer, N. Bannert, M. Landthaler, C. Goffinet* *Berlin*
15.45 – 16.00 ST 6	**Mycobacterium tuberculosis exploits WNT6/ACC2-induced storage of triacylglycerol-rich lipid droplets in macrophages** *J. Brandenburg[1], S. Marwitz[2], S. C. Tazoll[2], F. Waldow[2], B. Karlsdorf[2], T. Vierbuchen[2], T. Scholzen[2], A. Gross[2], S. Goldenbaum[2], A. Hölscher[2], M. Hein[2], L. Linnemann[2], M. Reimann[2], A. Kispert[3], M. Leitges[4], J. Rupp[5], C. Lange[2], S. Niemann[2], J. Behrends[2], T. Goldmann[2], H. Heine[2], U. Schaible[2], C. Hölscher[2], D. Schwudke[2], N. Reiling[1]* *[1, 2] Borstel, [3] Hannover, [4] St. John's (Canada), [5] Lübeck*
16.00 – 16.15 AT 2	**Liver-resident virus-specific CD8 T cells in a preclinical model of persistent HBV infection** *M. Bosch[1], N. Kallin[1], S. Donakonda[1], M. Hofmann[2], C. Ramirez[3], L. Swadling[4], L. J. Pallett[4], D. J. Zhang[5], C. Hermann[3], U. Protzer[6, 7], M. Maini[4], S. Luangsay[5], R. Thimme[2], D. Zehn[8], D. Wohlleber[1], P. Knolle[1]* *[1, 6, 7, 8] Munich, [2] Freiburg, [3] Heidelberg, [4] London (United Kingdom), [5] Basel (Switzerland)*

ST = Short Talk, AT = Academy Talk

16.15 – 17.15 Room Maritim	**Poster Session II** **Chronic Infections** For further information please see page 23
From 19.00	**Get-together & Classic Concert**



09.00 – 11.00 Main Hall	**Symposium III: Tropical and Emerging Infections** *Chairs: J. Reinhard-Rupp, Geneva/CH* *S. Schmiedel, Hamburg*
09.00 – 09.15	**Overview – Tropical and Emerging Infections** *D. Heinz, Braunschweig*
09.15 – 09.30	**A year in review** *M. Addo, Hamburg*
09.30 – 10.00	**Progress, challenges and opportunities in the fight against malaria** *P. Alonso, Barcelona/Spain*
10.00 – 10.15 ST 7	**Protection against heterologous controlled human malaria infection (CHMI) by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial in an European study population** R. Fendel[1, 2, 3], Z. Sulyok[1, 3], B. Eder[2, 3], F.-R. Lorenz[1, 3], N. Kc4, M. Karnahl[1, 3], A. Lalremruata[1, 3], T. T. Nguyen[1, 3], J. Held[1, 2, 3], A. Folashade Almeine Cyntiche[1, 3], T. Klockenbring[5], J. Flügge[1, 2, 3], T. W. Gebru[1, 3], C. Lamsfus Calle[1, 3], J. Ibanez[1, 3], M. Rodi[1, 3], D. Egger-Adam[1, 3], A. Kreidenweiss[1, 3], C. Köhler1[1, 2, 3], M. Esen[1, 2, 3, 6], M. Sulyok[1, 3], A. Manoj[4], T. L. Richie[4], B. K. L. Sim[4], S. L. Hoffman[4], B. Mordmüller[1, 2, 3, 7], P. G. Kremsner[1, 2, 3] [1, 3, 6] Tübingen, [2] Lambaréné (Gabon), [4] Rockville (United States), [5] Aachen, [7] Nijmegen (Netherlands)
10.15 – 10.30 ST 8	**Clinical Stability of the human gut microbiome and macrofauna: a phase 1 randomized, placebo-controlled, participant blinded, gut microbiota-depletion trial in intestinal helminth infected adults living in Lambaréné Gabon.** A. Alabi[1, 2], S. Agnandji[1, 3] [1]Lambaréné (Gabon), [2]Leiden (Netherlands), [3]Tübingen
10.30 – 10.45 ST 9	**The T-Cell Activation Marker For TB (TAM-TB) in "RaPaed-TB" – A New Diagnostic Tool For Paediatric TB** L. Olbrich[1, 2, 3], H. Zar[4], I. Sabi5, N. Ntinginya[5], C. Khosa[6], D. Banze[6], M. Nliwasa[7], E. Corbett[7, 8], V. Verghese[9], J. Michael[10], S. Graham[11], P. Nabeta[12], A. Trollip[12], M. Ahmed[1, 2], K. Held[1, 2], M. Hölscher[1, 2], C. Geldmacher[1, 2], N. Heinrich[1, 2]; [1, 2] Munich, [3] Oxford (United Kingdom), [4] Cape Town (South Africa), [5] Mbeya (Tanzania), [6] Maputo (Mozambique), [7] Blantyre (Malawi), [8] London (United Kingdom), [9, 10] Vellore (India), [11] Melbourne (Australia), [12] Geneva (Switzerland)
10.45 – 11.00 AT 3	**Quantification of Wolbachia endosymbionts from few Onchocerca volvulus microfilariae using qPCR - establishment and validation of a tool for longitudinal monitoring of new anti-wolbachial drug treatment success** S. Schlabe[1, 2, 3], P. Korir [2, 3], C. Lämmer [2, 3], F. Landmann[4], B. Dubben [2, 3], M. Koschel [2, 3], A. Albers[2, 3], L. B. Debrah[5, 6], A. Y. Debrah[5, 7], M. P. Hübner[2, 3], K. Pfarr[2, 3], U. Klarmann-Schulz [2, 3, 8], A. Hoerauf [2, 3] [1, 2, 3, 8] Bonn, [4] Montpellier (France), [5, 6, 7] Kumasi (Ghana)

ST = Short Talk, AT = Academy Talk

11.00 – 11.30	**Coffee Break and Industrial Exhibition**
11.30 – 11.50 Main Hall	**Human Monkeypox in 2022** *A. Volz, Hannover*
11.50 – 12.30 Main Hall	**DZIF Award Lectures** *Chairs: H.-G. Kräusslich, Heidelberg* *J. Rupp, Lübeck* **Award winners 2020/2021**
12.30 – 12.45	**Group Photo**
12.45 – 14.15 Salon Hamburg	**DNDi Symposium** DNDi's Strategic Plan 2021-2028 · COVID-19 & Pandemic preparedness · Deep dive into NTD activities and new portfolio · Transversal topics
12.45 – 14.15 Salon Bonn	**TI BBD Workshop** TI BBD World Café – Open workshop of the DZIF TI Bioresources, Biodata and Digital Health The workshop addresses all interested scientists and PhDs which are involved in bioresource collection, study planning and biodataanalyses/ management. In the World Café, the TI BBD would like to discuss and explain the options how analyses and translational research with biomaterials can be improved.
12.45 – 14.45	**Lunch Break and Industrial Exhibition and Poster Session**
13.15 – 14.15 Main Hall	**MSD Symposium** **Pandemics on the rise: Covid-19 and Multidrug-Resistant Pathogens** *Chair: M. Pletz, Jena* **INCATE – The Incubator for Antibacterial Therapies in Europe** *S. Alt, Braunschweig* **Target-based anti-infective discovery** *A. Hirsch, Saarbrücken* **Hot Topic Covid-19: Opportunities and challenges for COVID-19 treatments** *M. Pletz, Jena* The symposium is organized by MSD Sharp & Dohme GmbH, Munich.

SCIENTIFIC PROGRAMME
THURSDAY, 2 JUNE 2022



13.45 – 14.45 Room Maritim	**Poster Session III:** **Tropical and Emerging Infections** For further information please see page 30
14.45 – 16.45 Main Hall	**Symposium IV: Antimicrobial Resistance** *Chairs: C. Lange, Borstel* *A. Zinkernagel, Zurich/CH*
14.45 – 15.00	**Overview – Antimicrobial Resistance** *A. Peschel, Tübingen*
15.00 – 15.15	**Antibiotic Treatment of Carbapenem-resistant Gram-negative Infections – one size fits all** *M. Pletz, Jena*
15.15 – 15.45	**Understanding difficult-to-treat Staphylococcal infection** *A. Zinkernagel, Zurich/CH*
15.45 – 16.00 ST 10	**Pathogen sequencing for design of multidrug-resistant tuberculosis treatment regimens** *H.-P. Grobbel[1], M. Merker[2], N. Köhler[1], S. Andres[3], H. Hoffmann[4], J. Heyckendorf[1], M. Reimann[1], I. Barilar[2], V. Dreyer[2, 5], D. Hillemann[3], B. Kalsdorf[1, 5], T. Kohl[2], P. Sanchez-Carballo[1], D. Schaub[1], K. Todt[1], C. Utpatel[2], F. Maurer[3], C. Lange[1, 5], S. Niemann[2, 5]* *[1, 2, 3, 5] Borstel, [4] Gauting*
16.00 – 16.15 ST 11	**A chronic lung infection model with P. aeruginosa for evaluation of novel anti-infectives** *Rox, K.[1,2], Pils, M.[3], Häussler, S. C.[4], Medina, E.[5,6]* *[1,3,4,5] Braunschweig, [2,6] Partner Site Hannover-Braunschweig*
16.15 – 16.30 ST 12	**Development of novel epoxidized chlorotonil derivatives as anti-infective agents** *W. Hofer[1], E. Oueis[1], A. A. Fayad[1], A. Andreas[1], F. Deschner[1], S. Hüttel[2, 3], L. Pessanha de Carvalho[4], K. Jungmann1[1, 2], B. Morgenstern[5], M. Stadler[2, 3], J. Held[4, 6, 7], J. Herrmann[1], R. Müller[1, 2]* *[1, 5] Saarbrücken, [2, 3] Braunschweig, [4, 6] Tübingen, [7] Lambaréné (Gabon)*
16.30 – 16.45 AT 4	**Klebsiella oxytoca mediates colonization resistance against multi-drug resistant K. pneumoniae in the gut via cooperative carbohydrate competition** *L. Osbelt[1, 2], M. Wende[1, 2], E. Almási[1], E. Derksen[1], U. Muthukumarasamy[1], T. R. Lesker[1], E. J. C. Galvez[1], M. Pils[3], E. Schalk[4], P. Chhatwal[5], J. Färber[6], M. Neumann-Schaal[7], T. Fischer[2,4], D. Schlüter[2, 5], T. Strowig[1, 8, 9, 10]* *[1, 3, 7] Braunschweig, [2, 4, 6, 8] Magdeburg, [5, 9] Hannover, [10] Cologne*

ST = Short Talk, AT = Academy Talk

16.45 – 17.45 Room Maritim	**Poster Session IV** **Antimicrobial Resistance** For further information please see page 44
From 18.00	**Get together with Jazz & DGI/DZIF Awards** **DZIF-Doktorandenpreise der DGI 2022** **Poster Awards**



09.00 – 11.00 Main Hall	**Symposium V: COVID I** *Chairs: J. Malin, Cologne* *B. Jensen, Düsseldorf*
09.00 – 09.40	**Epidemie und Pandemie Intelligence: Was haben wir aus der COVID Pandemie gelernt** *J. Fitzner, Geneva/CH*
09.40 – 10.20	**Epidemiology** *B. Lange, Braunschweig*
10.20 – 11.00	**Prevention** *T. Schmidt, Homburg/Saar*
11.00 – 11.30	**Coffee Break & Industrial Exhibition**
11.30 – 13.30 Main Hall	**Symposium VI: COVID II** *Chairs: B. Salzberger, Regensburg* *B. Lange, Braunschweig*
11.30 – 12.10	**Diagnostic** *C. Drosten, Berlin*
12.10 – 12.50	**Therapy** *B. Salzberger, Regensburg*
12.50 – 13.30	**Long-COVID** *R. Koczulla, Schoenau*
13.30	**Closing Remarks** *H. Broetz-Oesterhelt, Tuebingen* *C. Lange, Borstel*

Poster Sessions

The poster exhibition will take place in room Maritim.
Posters shall be prepared in **DIN A0 size (841 x 1189 mm)**, portrait format, in the English language. The dimensions of the poster walls are 1200 mm (width) x 1500 mm (height), material to fix the posters in place will be provided.

Session "Immune Prevention and Therapy" and Session "Chronic Infections"
Posters should be mounted on Wednesday, 1 June 2022 from 08.00 – 09.30 and removed from 19.00 – 20.00.
Session "Tropical and Emerging Infections" and Session "Antimicrobial Resistance"
Posters should be mounted on Thursday, 2 June 2022 from 08.00 – 10.00 and removed from 19.00 – 20.00.

Please note remaining posters cannot be stored and will be disposed of.
The authors are kindly asked to be present at their posters during their poster sessions for questions and discussion:

Poster Session **"Immune Prevention and Therapy"** on Wednesday, 1 June 2022 from 13.15 – 14.15
Poster Session **"Chronic Infections"** on Wednesday, 1 June 2022 from 16.15 – 17.15
Poster Session **"Tropical and Emerging Infections"** on Thursday, 2 June 2022 from 13.45 – 14.45
Poster Session **"Antimicrobial Resistance"** on Thursday, 2 June 2022 from 16.45 – 17.45

Poster Awards

The four best posters will be awarded with 500,- EUR each. The presentation of the awards will take place on Thursday, 2 June 2022, from 18.00 during the Get together with jazz.

Our sincere thanks go to MSD Sharp & Dohme GmbH for its support.

DZIF Prize for Translational Research

The DZIF will award the DZIF Prize for Translational Infection Research endowed with 5.000,- EUR. The prize will be awarded on Thursday, 2 June 2022 from 11.30 - 12.30. The winners from 2020 and 2021 will also present results of their research.

Abstract Book

The Abstract Book will be available online at the conference website.



DZIF TI-Forum

At the same time of the poster sessions, representatives of following DZIF Translational Infrastructures (TI) will present their services:

TI BBD
Biodata, Bioressources & Digital Health

Take advantage of the opportunity to find out how the TI can support your research.

Meeting of the DZIF Academy fellows and Steering Committee during the Get-together
Wednesday, 1 June 2022, from 19.00, Foyer

Get to know other DZIF Academy fellows and the Steering Committee. Learn more about opportunities, news and events of the DZIF Academy:
The meeting offers young scientists the possibility to expand their network and to exchange information with other fellows. Take advantage of the opportunity to learn from and with each other. There will be ample scope for discussing and developing ideas concerning present and future academic activities.

IMMUNE PREVENTION AND THERAPY

P 001
Transcriptional profiling and single-cell chimerism analysis identify human tissue-resident host T cells in the skin after allogeneic stem cell transplantation
G. Almeida[1], C. Zielinski[2]
[1]Munich, [2]Jena

P 002
Candida albicans specific T cells produce the innate danger signal IL-1a and are regulated by the inflammasome.
A. Puhach, C. Zielinski
Jena

P 003
Distinct regulation of IL-13 and IL-4 producing T helper cells – implications for host defense against parasitic infections
C. Zielinski[1], J. Matthias[2]
[1]Jena, [2]Berlin

P 004
Nasal commensals reduce Staphylococcus aureus proliferation by restricting siderophore availability
Y. Zhao, D. Belikova, L. Adolf, J. Power, S. Heilbronner
Tübingen

P 005
Seroprevalence of humoral immunity against Staphylococcus aureus vaccine candidate Coproporphyrinogen III oxidase (CgoX)
L. Maus, A. Gluschko, M. Herb, M. Gonzalez Rodriguez, K. Wiegmann, D. Grumme, S. Mertins, A. Klimka, M. Krönke, Cologne

P 006
Staphylococcus aureus defeat phagocytes from inside through Coproporphyrinogen III oxidase-mediated default porphyrin metabolism
M. Herb, A. Gluschko, S. Brodesser, A. Farid, D. Grumme, K. Wiegmann, M. Krönke
Cologne

P 007
The DZIF Transplantation Cohort e.V
D. Schindler, The DZIF Transplantation Cohort e.V. Consortium
München

P 008
Remote audits as tool to assess sample quality for DZIF transplant cohort in times of COVID-19
A. Kühn-Steven[1], M. K. Tauchert[1, 2], E. Dumann[3], D. Pohle[4], C. Sommerer[5], D. Schindler[6], G. Anton[1], Transplant Cohort Consortium
[1]Neuherberg, [2]Graz, [3]Hanover, [4]Tuebingen, [5]Heidelberg, [6]Munich



P 009
Late third immunization with the MVA-MERS-S vaccine candidate enhances frequencies of spike-specific B cells, antibody persistence and non-neutralizing functionality
L. M. Weskamm[1], A. Fathi[1], T. Koch[1], M. Friedrich[1], S. Becker[2], G. Sutter[3], A. Volz[3, 4], T. Hesterkamp[4, 5], B. Haagmans[6], C. Dahlke[1], M. M. Addo[1]
[1]Hamburg, [2]Marburg, [3]München, [4]Hannover, [5]Braunschweig, [6]Rotterdam

P 010
Identification and characterization of human monoclonal antibodies neutralising HEV
K. Dinkelborg[1], G. Ssebyatika[2], P. L. Nankya[2], E. M. Guzmán[2], L. J. Ströh[1], L. Hüffner[1], V. Kinast[3, 4], T. L. Meister[3], H. Wedemeyer[1], E. Steinmann[3], T. Pietschmann[1], T. Krey[1, 2, 5], P. Behrendt[1]
[1]Hannover, [2]Lübeck, [3]Bochum, [4]Oldenburg, [5]Hamburg

P 011
Targeted mass spectrometry detection of candidate human papillomavirus T cell epitopes for major HLA supertypes
J. D. Förster, M. Salek, N. Vuckovic, K. Öhlenschläger, R. Köhler, M. Bonsack, A. B. Riemer
Heidelberg

P 012
Phenotypical and functional characterization of tissue-resident T cells during Helicobacter pylori infection with impact on prophylactic vaccination strategies
V. Friedrich, M. Koch, R. Gong, R. Semper, B. Lugen, S. Jarosch, R. Mejias-Luque, M. Gerhard
Munich

P 013
Influence of HCMV variants expressing NKG2D ligands on immune cell activation
G. Meyer[1], R. Siemes[1], J. Kuehne[1], J. Keil[1], K. Beushausen[1], K. Wagner[1], L. Steinbrück[1], E. M. Borst[1], M. Messerle[1, 2], C. Falk[1, 2]
[1]Hannover, [2]Braunschweig/Hannover

P 014
Assessing the humoral immune response following SARS-CoV-2 infection in children with MULTICOV-AB
H. Renk[1], A. Dulovic[2], P. Henneke[3], A. R. Franz[1], K.-M. Debatin[4], N. Schneiderhan-Marra[2], A. Janda[4], R. Elling[3], Baden-Württemberg COVID-19 in Children Study Group
[1]Tübingen, [2]Reutlingen, [3]Freiburg, [4]Ulm

P 015
Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE)
I. Hrabal[1], K. Dinkelborg[2], P. Behrendt[2], M. Cornberg[2], H. Wedemeier[2], H. Völzke[3], M. Eiden[1], M. Groschup[1]
[1]Greifswald-Insel Riems, [2]Hannover, [3]Greifswald

P 016
MAIT cells from hematopoietic stem cell transplantation patients are less responsive to fungal stimulation
S. Jahreis, S. Böttcher, S. Hartung, M. von Lilienfeld-Toal
Jena

P 017
"Invasive aspergillosis-on-chip" – a customisable disease model to study the impact of immune cell composition on Aspergillus fumigatus infection in the human lung
M. T. N. Hoang, Z. Cseresnyés, S. Hartung, K. Rennert, A. S. Mosig, M. von Lilienfeld-Toal, M. T. Figge
Jena

P 018
Characterisation of MAIT cells in the antifungal immune response in a microfluidic "invasive aspergillosis-on-chip" disease model
S. Grau, S. Jahreis, S. Hartung, Z. Cseresnyés, M. Hoang, K. Rennert, A. S. Mosig, M. T. Figge, M. von Lilienfeld-Toal
Jena

P 019
Dendritic cell- and T cell-based immune therapies against Ebola virus disease
C. Olal[1], B. Bodmer[2], T. Hoenen[2], C. Muñoz-Fontela[1]
[1]Hamburg, [2]Greifswald - Insel Riems

P 020
Predicting host dependency factors of pathogens in Drosophila melanogaster using machine learning
O. Aromolaran[1], M. Oswald[2], T. Beder[3], E. Adedeji[1], Y. Ajamma[1], J. Oyelade[1], E. Adebiyi[1], R. Koenig[2]
[1]Ota, Otun State, [2]Jena, [3]Kiel

P 021
Determinants of the liver mucosal immune barrier are distinctly regulated in biliary atresia correlating with disease progression
J. Basenach, J. N. Hauser, A. Peschel, E. Sturm, C. Slavetinsky
Tübingen

P 022
Munich microfluidics based high-throughput PCR platform (Fluidigm Juno-Biomark HD)
K. Held, C. Geldmacher, M. Hölscher
Munich

P 023
Viral glycoproteins induce NLRP3 inflammasome activation and pyroptosis in macrophages.
H. Eisfeld[1], A. Simonis[1], T. Krey[2], M. Koch[1], S. Theobald[1], J. Rybniker[1]
[1]Cologne, [2]Luebeck

P 024
Raman spectroscopy is a powerful tool to characterize the immune response to infection
U. Neugebauer, D. Thomas-Rüddel, A. Ramoji, N. Arend, A. Pistiki, O. Ryabchykov, M. Kiehntopf, T. Bocklitz, I. W. Schie, F. Bloos, I. Rubio, J. Popp, M. Bauer
Jena



P 025
Investigating the treatment shorting potential of sutezolid-containing regimens in a murine model with confirmed drug exposures
K. Walter[1], L. te Brake[2], C. Hölscher[1], M. Hoelscher[3], E. Svensson[2], N. Heinrich[3]
[1]Borstel, [2]Nijmegen, [3]München

P 026
HIV vaccine design: Can we steer IgG recognition towards regions of viral vulnerability
A. Horvath[1], G. Pollakis[2], L. Rogers[1], L.-A. Eller[3], S. Joseph[2], H. Kibuuka[4], S. Rerks-Ngarm[5], P. Pitisuttithum[6], S. Nitayaphan[6], B. Graham[7], M. L. Robb[3], R. Shattock[2], J. Weber[2], M. Hoelscher[1], A. Kroidl[1], R. Wagner[8], K. Held[1], C. Geldmacher[1]
[1]Munich, [2]London, [3]Silver Spring, [4]Kampala, [5]Nonthaburi, [6]Bangkok, [7]Bethesda, Maryland, [8]Regensburg

P 027
Evaluation of neutralizing antibodies against SARS-CoV-2 infection
L. Abassi[1], F. Bertoglio[1], P. Heine[1], U. Rand[1], T. Schirrmann[1], M. Hust[1], L. Čičin-Šain[1, 2]
[1]Braunschweig, [2]Hannover-Braunschweig

P 028
Early recognition of HCMV-pp65 antigen by CD8 T cells
F. Khan[1, 2], T. Müller[3], M. A. Y. Durand[1, 2], B. Kasmapour[1, 2], D. Busch[3], L. Čičin-Šain[1, 2]
[1]Braunschweig, [2]Hannover-Braunschweig, [3]Munich

P 029
Neutrophil efferocytosis reprograms mitochondrial metabolism to switch alveolar macrophages to a pro-resolution phenotype at the cost of bacterial control
J. Better[1], M. Wetstein[1], M. Langelage[1], M. Estiri[1], I. Kuznetsova[1], C. Malainou[1], I. Vazquez-Armendariz[1], L. Kimmig[2], J. Wilhelm[1], I. Alexopoulos[1], N. Sommer[1], S. Herold[1], U. Matt[1]
[1]Giessen, [2]Chicago

P 030
Impact of High Dose Vitamin D_3 Supplementation on Innate Immunity and Antimicrobial Functions in Adolescents with HIV-1 on ART
C. Leschczyk[1], K. Sichibalo[1], P. Kelly[2], S. Rowland-Jones[3], U. E. Schaible[1], VITALITY-Team
[1]Borstel, [2]London, [3]Oxford

P 031
A GMP-compatible protocol for the production of CCR5-edited CAR-T cells from HIV-positive patients
L. I. Schwarze[1, 2], N. Nuppenau[1], J. H. Müller[1], T. Sonntag[1], S. Wild[3], S. Schmitz[3], A. Uhde[1], B. Fehse[1, 2]
[1]Hamburg, [2]partner site Hamburg, [3]Bergisch Gladbach

P 032
Innate immune responses and NLRP3 inflammasome activation induced by SARS-CoV-2 spike protein after vaccination
J. Mudler, S. Theobald, A. Simonis, J. Rybniker
Cologne

P 033
Cancelled

P 034
Blood cell-guided diagnosis and therapy monitoring of tuberculosis by using a novel artificial intelligence score
P. Sanchez Carballo[1], M. Reimann[1], D. Schaub[1], E. Tolosa[2], C. Lange[1, 3, 4], J. Heyckendorf[1, 5]
[1]Borstel, [2]Hamburg, [3]Lübeck, [4]Houston (Texas), [5]Kiel

P 035
T cell engager antibodies promote efficient recruitment of human PBMCs and reduction of HBV infection in the liver of humanized mice
A. Volmari[1, 2], O. Quitt[3], T. Volz[1, 2], L. Allweiss[1, 2], U. Protzer[3, 4], M. Dandri[1, 2]
[1]Hamburg, [2]Hamburg-Lübeck-Borstel-Riems and Heidelberg sites, [3]Munich, [4]Munich and Hamburg sites

P 036
Selective inhibition of conventional Protein kinase C isoforms restores the host response in a murine model of sepsis
L. Xiong, D. Beyer, S. Neugebauer, O. Sommerfeld, S. Nietzsche, M. Westermann, A. T. Press
Jena

P 037
Antibiotic treatments and gut microbiome dysbiosis as deteroriating factors regarding cellular immunotherapeutic strategies against hematologic malignancies.
C. Stein-Thoeringer
Heidelberg

P 038
Qualitätsgesichertes Biobanking - Akkreditierung der DZIF-Gewebebank
I. M. Klein, C. Kaufhold-Wedel, A. Brobeil, P. Schirmacher
Heidelberg

P 039
Establishment of a HPV16 E6/E7-dependent vaginal tumor model in MHC-humanized mice for development of therapeutic HPV16 vaccination strategies
S. Zottnick[1, 2], S. Kruse[1, 2], M. Bozza[1], A. L. Henneberg[1, 2], A. Klevenz[1, 2], R. Yang[1], F. Rösl[1], R. P. Harbottle[1], A. B. Riemer[1, 2]
[1]Heidelberg, [2]partner site Heidelberg

CHRONIC INFECTIONS

P 040
PHIMS-TB: Enhancing public health actions by an integrated molecular surveillance of tuberculosis in Germany
T. Kohl[1], S. Kröger[2], F. Maurer[1], L. Bös[2], L. Paulowski[1], M. Merker[1], V. Dreyer[1], M. Diercke[2], M. Huska[2], S. Niemann[1], W. Haas[2]
[1]Borstel, [2]Berlin

P 041
Influence of early ART-initiation on dynamics and functionality of follicular CD8 cells
S. Rüger[1], M. Münchhoff[1], K. Held[1], R. Stirner[1], R. Conca[1], I. Andrä[1], L. Rogers[1], K. Witter[1], E. Gersbacher[1], J. Eger[1], R. Pauli[1], N. Postel[1], C. D. Spinner[1], J. J. Vehreschild[2, 3], M. Stecher[3], H. Nitschko[1], J. Eberle[1], J. Bogner[1], R. Draenert[1], C. Geldmacher[1], J. Roider[1]
[1]Munich, [2]Frankfurt, [3]Cologne

P 042
Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative persistent HBV infection
A. Kosinska, J. Festag, M. Mück-Häusl, M. Festag, T. Asen, U. Protzer
München

P 043
Cancelled

P 044
Label-free, non-destructive visualization of intracellular bacteria using Coxiella burnetii as an example
N. Unger, S. Eiserloh, E. Liebler-Tenorio, C. Schnee, C. Berens, U. Neugebauer
Jena

P 045
Longitudinal study on prevalence, genotype distribution and associated risk factors of oropharyngeal human papilloma virus (HPV) infection after transplantation (DZIF-Transplant Cohort)
A. Klostermann, A. Iftner, K. Kegreiß, D. Pohle, The German Center for Infection Research (DZIF) Transplant Cohort Consortium, Site Tuebingen, J. Hädicke-Jarboui, T. Iftner, T. Ganzenmueller
Tübingen

P 046
Hepatitis C virus adaptation for the generation of a HCV mouse model
J. Sheldon[1], Q. Yuan[1], M. Winkler[1], N. Frericks[1], Y. Zhang[1], R. Brown[2], A. Carpentier[1], N. Gödecke[3], S. Behme[3], K. Rox[3], F. Vondran[1], S. Pöhlmann[4], D. Wirth[5], T. Pietschmann[1]
[1]Hannover, [2]Langen, [3]Braunschweig, [4]Göttingen, [5]Braunsweig

P 047
Human stem cell-derived hepatocytes as a model for hepatitis D virus infection
H. Chi, Bingqian Qu, Angga Prawira, Rebecca M. Fu, Florian A. Lempp, Charlotte C. Decker, Zhenfeng Zhang, Viet Loan Dao Thi, Stephan Urban
Heidelberg

P 048
A novel bead-based multiplex assay for the simultaneous detection of Borrelia specific IgG/M class antibodies
J. Häring[1], M. J. Hassenstein[2], M. Becker[1], J. Ortmann[2], D. Junker[1], H. Klein[3], C. von Eichel-Streiber[3], A. Karch[4], K. Berger[4], T. Tchitchagua[5], O. Leschnik[5], M. Harries[2], D. Gornyk[2], P. Hernández[2], B. Lange[2, 6], S. Castell[2, 6], G. Krause[2, 6], A. Dulovic[1], M. Strengert[2], N. Schneiderhan-Marra[1]
[1]Reutlingen, [2]Braunschweig, [3]Bingen, [4]Münster, [5]Rodewisch, [6]Hannover-Braunschweig

P 049
Establishment of a phenotypic Resistance-/Sensitivity-Test for Hepatitis C virus isolates from patient serum
N. Schäfer[1], C. Heuss[1], V. Laketa[1], U. Merle[1], J. Dietz[2], C. Sarrazin[2], P. Schnitzler[1], S. Olberg[1], V. Lohmann[1]
[1]Heidelberg, [2]Frankfurt

P 050
Novel antivirals targeting the human cytomegalovirus alkaline nuclease UL98
T. Zhang[1], T. Potgieter[1], J. Rückert[2], M. Empting[3], T. Schulz[2], W. Brune[1]
[1]Hamburg, [2]Hannover, [3]Saarbrücken

P 051
SPI-1 prolongs the intracellular survival and dissemination of Salmonella Typhimurium in macrophages
K. Ehrhardt[1], A.-L. Becker[1], J. Otte[1], S. Wagner[2], G. A. Graßl[1]
[1]Hannover, [2]Tübingen

P 052
Neutrophil-associated signatures for point-of-care testing to introduce personalized host-directed therapy in tuberculosis
C. Leschczyk[1], A. Bollen[1], J. Heykendorf[2], A. Rachow[3], D. Schwudke[1], C. Lange[1], U. E. Schaible[1], East European Study Site
[1]Borstel, [2]Kiel, [3]Munich

P 053
Female genital tract disorders in rural Madagascar: a prevalence study on Female Genital Schistosomiasis, Human Papilloma Virus and Cervical Cancer.
P. Rausche[1, 2], J.-M. Kutz[1, 2], R. Rakotoarivelo[3], T. Rasamoelina[4], R. S. Rakotomalala[5], S. Ratefiarisoa[5], M. Hampl[6], M. Lingenscheid[1, 2], E. Lorenz[1, 2], A. Jaeger[1, 2], T. Gheit[7], M. Tommasino[7], R. Rakotozandrindrainy[4], J. May[1, 2], D. Fusco[1, 2]
[1]Hamburg, [2]Hamburg-Borstel-Lübeck-Riems, [3]Fianarantsoa, [4]Antananarivo, [5]Mahajanga, [6]Düsseldorf, [7]Lyon



P 054
Microbiome alterations and the development of risk factors for irritable bowel syndrome in a cohort of German patients
D. Singh, V. Berndtke, M. Gerhard, R. Mejías-Luque, A. Schneider
München

P 055
Predicting HCMV reactivation and acute graft versus host disease in HSCT patients
P. Kay-Fedorov, C. Falk, E. Weissinger
Hannover

P 056
Do anti-TB drugs reach their target? – High resolution MALDI MS imaging provides information on drug penetration into necrotic granulomas
J. Kokesch-Himmelreich[1], A. Treu[1], K. Walter[2], A. Race[1], J. Dreisbach[3], N. Heinrich[3], M. Hölscher[3], C. Hölscher[2], A. Römpp[1]
[1]Bayreuth, [2]Borstel, [3]Munich

P 057
Establishment of a laboratory developed quantitative HEV PCR assay on the cobas6800 high throughput system for the detecting of HEV 1-8 and rat HEV RNA
D. Nörz[1], M. Grunwald[1], K. Giersch[1], L. Allweiss[1], M. Dandri[1], S. Pischke[1], R. Johne[1, 2], M. Lütgehetmann[1]
[1]Hamburg, [2]Berlin

P 058
Diagnosing schistosomiasis in Madagascar: Is there a compromise between field applicable and laboratory-based approaches?
C. O. Doumbia[1, 2, 3], R. Rakotozandrindrainy[4], R. R. Andry[5], R. Razafindrakoto[6], A. Zerbo[1, 7], Y. Höppner[1], H. von Thien[1], P. Rausche[1, 2], P. Klein[1], P. L. Corstjens[8], G. J. van Dam[8], A. Jaeger[1, 2], N. G. Schwarz[1, 2], E. Tannich[1, 2], J. May[1, 2], E. Lorenz[1, 2, 9], D. Fusco[1, 2]
[1]Bernhard-Nocht-Strasse 74, D-20359, Hamburg, [2]Hamburg-Borstel-Lübeck-Riems, [3]Bamako, [4]Antananarivo, [5]Fianarantsoa, [6]Antananarivo 101, [7]Oviedo, [8]Albinusdreef 2, 2333 ZA, Leiden, [9]Mainz

P 059
Management einer komplizierten systemischen Salmonellen-Infektion bei Immunsuppression – ein Fallbericht
J. Bruns, V. Keitel, Z. Halloul, A. Kaasch, W. Obst
Magdeburg

P 060
Lessons from humoral immune protection in natural HCV infection to guide vaccine design
D. Bankwitz[1], A. Bahai[2], M. Labhun[1], T. Weber[3], M. Doepke[1], C. Ginkel[1], L. J. Ströh[1], L. Dold[3], P. Behrendt[1, 2], M. Cornberg[1, 2], J. Dietz[4], C. Sarrazin[4, 5], F. Klein[2, 3], A. C. McHardy[2], T. Krey[1, 6, 7], T. Pietschmann[1, 2]
[1]Hannover, [2]Braunschweig, [3]Köln, [4]Frankfurt, [5]Wiesbaden, [6]Lübeck, [7]Hamburg

P 061
Highly efficient small molecule ihibitors block LMP1 signaling and interfere with LCL and PTLD survival
F. Giehler[1], S. Blazy[2], O. K. Tever[1], K. Rox[3], A. Kany[3, 4], K. Schorpp[1], S. Dornauer[1], K. Hadian[1], M. Empting[3, 4], O. Plettenburg[2], A. Kieser[1]
[1]Munich, [2]Hannover, [3]Braunschweig, [4]Saarbrücken

P 062
A Hepatitis C virus genotype 1b post transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo
C. Heuss[1], P. Rothhaar[1], R. Burm[2], N. Schäfer[1], U. Merle[1], R. Bartenschlager[1], T. Krey[3], V. Laketa[1], P. Meuleman[2], V. Lohmann[1]
[1]Heidelberg, [2]Ghent, [3]Lübeck

P 063
The K-APAT Study – Cologne Outpatient Parenteral Antimicrobial Therapy Program (OPAT)
V. Brandes[1], N. Scholten[1], C. Lindemann[1], C. Leisse[1], N. Baade[1], C. Oberröhrmann[1], S. Peter[1], M. Günther[1], N. Jung[1, 2], I. Suarez[1, 2], G. Paul[1, 3], C. Horn[1, 2], P. Schommers[1, 2], M. Augustin[1, 2], G. Fätkenheuer[1, 2], C. Lehmann[1, 2]
[1]Cologne, [2]Bonn-Cologne, [3]Stuttgart

P 064
Analysis of IgG and IgM specific epitope signatures and maturation of IgG avidity in chronic HEV infection
T. Schwarz, P. Tscheak, B. Eberspächer, J. Hofmann, V. M. Corman
Berlin

P 065
Pathogenic CD8 T cells defined by longitudinal liver sampling in chronic hepatitis B patients starting antiviral therapy
S. Nkongolo[1, 2], D. Mahamed[1], A. Kuipery[1], J. D. Sanchez Vasquez[1], S. C. Kim[3], A. Mehrotra[1], A. Patel[1], C. Hu[1], I. McGilvray[1], J. J. Feld[1], S. Fung[1], D. Chen[3], J. J. Wallin[3], A. Gaggar[3], H. L. A. Janssen[1, 4], A. J. Gehring[1]
[1]Toronto, [2]Heidelberg, [3]Foster City, [4]Rotterdam

P 066
Surgical procedure time and mortality in patients with infective endocarditis caused by Staphylococcus aureus or Streptococcus species
G. Paul[1, 2], L. Ochs[1], C. Hohmann[1], S. Baldus[1], G. Michels[3], C. Meyer-Schwickerath[1], G. Fätkenheuer[1], N. Mader[1], T. Wahlers[1], C. Weber[1], N. Jung[1]
[1]Cologne, [2]Stuttgart, [3]Eschweiler

P 067
The role of the restriction factor SMC5/6 complex in HBV infection and antiviral treatment in vivo
L. Allweiss[1, 2], M. Calaminus[1], K. Giersch[1], T. Volz[1], A. Pirosu[1], M. Lütgehetmann[1, 2], M. Dandri[1, 2]
[1]Hamburg, [2]Hamburg-Lübeck-Borstel-Riems Partner Site



P 068
Early identification of impaired T cell responses in patients with novel post-COVID syndrome (PCS)
F. Heyn, S. Ullrich, S. Theobald, U. Sandaradura de Silva, M.-C. Albert, M. Schlotz, P. Schommers, L. Gieselmann, F. Dewald, E. Pracht, C. Horn, I. Suarez, V. Brandes, G. Fätkenheuer, H. Gruell, F. Klein, M. Hallek, H. Walczak, J. Rybniker, C. Lehmann, M. Augustin
Cologne

P 069
Identification of small chemical compounds targeting capsid and virion assembly of Herpes Simplex Virus
J. Villalvazo[1, 2], L. Deng[1, 2], T. Richardo[1], A. Pohlmann[1], A. Binz[1, 2], A. Buch[1], D. Otoo[1], N. Arisetti[2, 3], K. Wagner[2, 3, 4], R. Bauerfeind[1], T. F. Schulz[1, 2], M. Brönstrup[2, 3], M. Empting[2, 3, 4], B. Sodeik[1, 2]
[1]Hannover, [2]Hannover-Braunschweig Site, [3]Braunschweig, [4]Saarbrücken

P 070
Ungewöhnliche Präsentation eines zerebralen Tuberkuloms bei einem immunkompetenten 4-jährigen Jungen
S. Wolff, A. Herz, M. Lauten, J. Gliemroth, T. Boppel, J. Rupp, F. Waldeck
Lübeck

P 071
Efficacy of albendazole and ivermectin based regimens for the treatment of microfilaremic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trial
R. Zoleko-Manego[1, 2], R. Kreuzmair[1], W. Ndoumba Nzebe[1], G. Mombo-Ngoma[1, 2], M. Ramaharter[2]
[1]Lambaréné, [2]Hamburg

P 072
Panobinostat and Romidepsin enhance Tax transcription but only moderately Tax protein in Tax-expressing, HTLV-1-infected cultured and patients' T-cells
A. P. Schnell[1], S. Kohrt[1], A. Aristodemou[2], G. P. Taylor[2], C. R. M. Bangham[2], A. K. Thoma-Kress[1]
[1]Erlangen, [2]London

P 073
Assessment of tuberculosis disease activity in people living with HIV and iinfected with Mycobacterium tuberculosis
I. Kroidl[1], M. I. Ahmed[1], S. Horn[1], C. Polyak[2, 3], A. Esber[2, 3], A. Parikh[2, 3], L. A. Eller[2, 3], H. Kibuuka[4], M. Semwogerere[4], B. Mwesigwa[4], P. Naluyima[4], J. Maswai[3, 5], E. Rono[5], R. Loose[1], M. Hoelscher[1], J. Ake[2], C. Geldmacher[1]
[1]Munich, [2]Silver Spring, [3]Bethesda, [4]Kampala, [5]Kericho

P 074
Spatially resolved characterization of lung material from tuberculosis patients
S. Marwitz[1], N. Shubladze[2], S. Vashakidze[2], U. Schaible[1, 3], T. Dallenga[1,3]
[1]Borstel, [2]Tbilisi, [3]Borstel Site

P 075
Dynamics of humoral and T-cell immunity after two and three BNT162b2 vaccinations in people over 80 years old.
A. J. Romero Olmedo[1], A. R. Schulz[2], S. Hochstätter[1], D. Das Gupta[1], H. Hirseland[2], D. Staudenraus[1], B. Camara[1], K. Volland[1], V. Hefter[1], S. Sapre[1], V. Krähling[1], H. Müller-Kräuter[1], H.-R. Chung[1], H. E. Mei[2], C. Keller[1], M. Lohoff[1]
[1]Marburg, [2]Berlin

P 076
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing
S. Donakonda, M. Luedemann, D. Stadler, C.-C. Cheng, U. Protzer, P. Knolle
Munich

P 077
Establishing novel therapeutic compounds against Helicobacter pylori motility and flagella and target identification
L. Patel[1], S. Suerbaum[1, 2], N. Coombs[1], D. Pscheniza[1], K. Rox[3], C. Falk[4], A. Gruber[5], O. Kershaw[5], P. Chhatwal[1], U. Bilitewski[3], M. Brönstrup[3], C. Josenhans[1, 2]
[1]80336 München, [2]Muenchen, [3]Braunschweig, [4]Hannover, [5]Berlin

P 078
Novel heterozygous IRF2BP2 mutations in CVID patients
M. Anim[1], G. Sogkas[1], N. Camacho Ordonez[2], N. Dubrowinskaja[1], M. Proietti[1, 2], B. Grimbacher[2], T. Witte[1], F. Atschekzei[1]
[1]Hannover, [2]Freiburg

P 079
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: A multicenter, single arm, phase 2 Study (the HepNet acute HCV V study)
B. Maasoumy[1], P. Ingiliz[2], C. D. Spinner[3], C. Cordes[2], H.-J. Stellbrink[4], J. Schulze zur Wiesch[4], S. M. Schneeweiß[5], K. Deterding[6], T. Müller[2], J. Kahlhöfer[1], P. Dörge[1], M. von Karpowitz[1], M. P. Manns[1], H. Wedemeyer[1], M. Cornberg[1], The HepNet Acute HCV-V Study Group
[1]Hannover, [2]Berlin, [3]München, [4]Hamburg, [5]Köln, [6]Essen

P 080
Lipobiotin-capture magnetic bead assay for isolation, enrichment and detection of Mycobacterium tuberculosis from saliva
J. Hansen[1], K. Kolbe[1], I. R. König[2], R. Scherliess[3], M. Hellfritzsch[3], S. Malm[1], J. Zallet[1], D. Hillemann[1], K.-H. Wiesmüller[4], C. Herzmann[1], J. Brandenburg[1], N. Reiling[1]
[1]Borstel, [2]Lübeck, [3]Kiel, [4]Tübingen

P 081
Epidemiology of Pseudomonas aeruginosa in people with non-CF-bronchiectasis
N. Cramer, I. M. Lüdemann, I. Rosenboom, L. Sedlacek, F. Ringshausen, T. Welte, B. Tümmler, N. Cramer
Hannover



P 082
Competitive fitness experiments of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices
N. Cramer, M. L. Nawrot, L. Wege, M. Dorda, C. Sommer, O. Danov, S. Wronski, A. Braun, D. Jonigk, S. Fischer, A. Munder, B. Tümmler
Hannover

P 083
Competitive survival of longitudinal Pseudomonas aeruginosa isolates of Cystic Fibrosis patients in presence of neutrophil granulocytes
P. Kuschnerow, A. Munder, N. de Buhr, A. C. Jirmo, M. Ackermann, M. von Köckritz-Blickwede, B. Tümmler, N. Cramer
Hannover

P 084
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results From the SALSA Study
P. Kumar[1], A. Clarke[2], C. Jonsson-Oldenbüttel[3], M. García Deltoro[4], S. Di Giambenedetto[5], C. Brites[6], L. Hocqueloux[7], P.-L. Lu[8], J. Oyee[9], J. Priest[10], E. Blair[10], A. Oglesby[10], B. Wynne[10], L. Gordon[10], E. Letang[11], J. van Wyk[9], S. Kreuzaler[3], L. Evitt[9]
[1]Washington, DC, [2]Brighton, [3]Munich, [4]Valencia, [5]Rome, [6]Salvador, [7]Orléans, [8]Kaohsiung, [9]Brentford, [10]Research Triangle Park, [11]Madrid

P 085
Long-term Inflammation Biomarker Changes With Fostemsavir in Heavily Treatment-Experienced Adults With HIV-1: Exploratory Analyses of the Phase 3 BRIGHTE Study
A. Clark[1], D. Asmuth[2], S. Chabria[3], A. Pierce[4], P. Ackerman[3], M. Wang[5], F. Du[5], J. Jeffrey[4], J. Goldbach[6], M. Lataillade[3]
[1]Brentford, [2]Sacramento, [3]Branford, [4]Research Triangle Park, [5]Collegeville, [6]Munich

P 086
Identification of potent HCMV trimer and pentamer specific neutralizing antibodies
M. Zehner[1], M. Alt[2], A. Ashurov[1], K. Laib Sampaio[3], R. Spies[3], N. Weiler[3], D. Stöhr[3], C. Stegmann[4], M. S. Ercanoglu[1], L. Gieselmann[1], C. Kreer[1], R. Lotfi[3], B. J. Ryckman[4], A. Krawczyk[2], C. Sinzger[3], F. Klein[1]
[1]Cologne, [2]Essen, [3]Ulm, [4]Missoula, Montana

P 087
The Stem Cell Niche of Mycobacterium tuberculosis
P. Engling[1], G. F. Melchers[2], U. E. Schaible[1]
[1]Borstel, [2]Berlin

P 088
Characterization of MEP pathway inhibitors in Mycobacterium tuberculosis as antituberculotics.
V. Sonawane[1], A. Lacour[2], A. Hirsch[2], N. Reiling[1]
[1]Borstel, [2]Saarbrücken

P 089
Novel Inhibitors against Kaposi's Sarcoma-associated Herpesvirus (KSHV)
A. Berwanger[1, 2], S. C. Stein[3], A. Kany[1], B. Loretz[1], C.-M. Lehr[1], T. F. Schulz[2, 3], M. Empting[1, 2]
[1]Saarbrücken, [2]Braunschweig, [3]Hannover

P 090
12-Month Outcomes of Dolutegravir (DTG) + Lamivudine (3TC) in ART-Naive and Pre-treated People Living With HIV in Germany: Real-world Data From the German URBAN Cohort
S. Scholten[1], S. Noe[2], C. Wyen[1], D. Beer[3], N. Postel[2], O. Degen[4], R. Pauli[2], H. Hillenbrand[5], B. Westermayer[2], K. Dymek[2], S. Kreuzaler[2], J. Scherzer[2]
[1]Cologne, [2]Munich, [3]Aachen, [4]Hamburg, [5]Berlin

P 091
Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials
E. Elliot[1], J. Polli[2], P. Patel[2], L. Garside[3], R. Grove[3], V. Barnett[2], J. Roberts[4], S. Ford[2], H. Crauwels[5], E. Birmingham[6], R. D'Amico[2], B. Baugh[7], S. Kreuzaler[8], M. Bosse[2]
[1]Madrid, [2]Research Triangle Park, [3]Brentford, [4]Mississauga, [5]Beerse, [6]Raritan, [7]Titusville, [8]Munich

TROPICAL AND EMERGING INFECTIONS

P 092
Convalescent COVID-19 patients without comorbidities display similar immunophenotypes over time despite divergent disease severities
C.-F. Chu, C. Zielinski, Jena

P 093
Accuracy of rapid point-of-care antigen-based diagnostics for SARS-CoV-2: an updated systematic review and meta-analysis with meta regression analyzing influencing factors
L. E. Brümmer[1], S. Katzenschlager[1], S. McGrath[2], S. Schmitz[3], M. Gaeddert[1], C. Erdmann[4], M. Bota[5], M. Grilli[6], J. Larmann[1], M. A. Weigand[1], N. R. Pollock[2], A. Mace[7], B. Erkosar[7], S. Carmona[7], J. A. Sacks[7], S. Ongarello[7], C. M. Denkinger[1]
[1]Heidelberg, [2]Boston, Massachusetts, [3]Rotterdam, [4]Münster, [5]Hamburg, [6]Mannheim, [7]Geneva

P 094
Updates from a malaria birth cohort in rural Ghana
N. S. Struck[1, 2], R. Krumkamp[1, 2], A.-M. Ginsbach[1], F. Boateng[3], J. Brinkel[1], L. Rautmann[1], K. Oppong[3], B. Agyemang[3], J. Puradiredja[1], E. Lorenz[1, 2, 4], W. Loag[1], J. Kettenbeil[1], N. Sarpong[3], J. H. Amuasi[3], O. Maiga-Ascofaré[1, 2], E. Mertens[1], J. May[1, 2]
[1]Hamburg, [2]Hamburg-Borstel-Lübeck-Riems, [3]Kumasi, [4]Mainz



P 095
Differential recognition of live and heat-killed Orientia tsutsugamushi by Toll-like receptors 3, 7 and 13 in mice is associated with altered RNA content after inactivation
J. Mehl[1], Z. Orfanos[1], L. Schulte[1], C. Kirschning[2], S. Bauer[1], C. Keller[1]
[1]Philipps-University Marburg, [2]University of Duisburg-Essen

P 096
Follow-up of survivors of Lassa Fever in Edo State, Nigeria: Study of correlates of immunity
A. Thielebein[1, 2], Y. Ighodalo[3], T. Olokor[3], R. Esumeh[3], R. Omiunu[3], A. Taju[3], A. Ekanem[3], M. Hinrichs[1, 2], J. Müller[1, 2], N. Akpede[3], D. Ehichioya[1, 3], D. Asogun[3], D. Adomeh[3], L. Oestereich[1, 2], S. Duraffour[1, 2], S. Günther[1, 2], E. Ogbaini-Emovon[3]
[1]Hamburg, [2]Partner site Hamburg, [3]Irrua, Edo State

P 097
RNA from Orientia tsutsugamushi induces inflammation via TLR8 in human THP-1 macrophages
M. Wagner, J. Mehl, L. Schulte, S. Bauer, C. Keller
Marburg

P 098
The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in Gabon
J. B. P. Agbo Achimi Abdul[1], R. C. Mevyann[1], M. Epola Dibamba Ndanga[1], B. R. Adegbite[1], C. Mebiame Biyogho[1], J. R. Edoa[1], G. A. R. Mfoumbi Ibinda[1, 2], A. A. Adegnika[1, 3, 4], M. P. Grosbusch[1, 3, 5]
[1]Lambaréné, [2]Franceville, [3]Tübingen, [4]Leiden, [5]Amsterdam

P 099
Exploring beyond clinical routine SARS-CoV-2 serology using MULTICOV-AB
M. Becker[1], M. Strengert[2, 3], D. Junker[1], A. Dulovic[1], B. Traenkle[1], P. D. Kaiser[1], J. Häring[1], A. Zeck[1], U. Rothbauer[1, 4], G. Krause[2, 3], N. Schneiderhan-Marra[1]
[1]Reutlingen, [2]Braunschweig, [3]Hannover, [4]Tübingen

P 100
Bioavailability and Stability Enhanced Solid Oral Formulations of the Anti-Infective Corallopyronin A
A. K. Krome[1], T. Becker[1], S. Kehraus[1], A. Schiefer[1], M. P. Hübner[1], K. Pfarr[1], T. Hesterkamp[2], G. M. König[1], A. Hoerauf[1], K. G. Wagner[1]
[1]Bonn, [2]Braunschweig

P 101
Two-stage development of a recombinant Modified Vaccinia virus Ankara expressing Lassa virus glycoprotein
A. Tscherne[1], G. Kalodimou[1], J. H. Schwarz[1], S. Jany[1], A. Freudenstein[1], A. Volz[1, 2], G. Sutter[1]
[1]Munich, [2]Hannover

P 102
Prevalence of opportunistic intestinal parasites in children under five years of age in the city of Nouna: Burkina Faso
M. Nikiema[1], B. Coulibaly[1], A. Gneme[2], D. Kiemde[1], C. Dah[1], M. Bountogo[1], A. Ouedraogo[1], A. Sie[1]
[1]Nouna, [2]Ouagadougou

P 103
Deep learning for histological analysis of onchocerciasis nodules
J. M. Kuehlwein[1, 2], D. A. Kuehlwein[3], J. Poplawska[4], B. Dubben[1], K. Fischer[5], M. Bergmann[6], M. Rickmers[1], M. Schmid[1], A. Y. Debrah[7], S. Specht[8], A. Hoerauf[1, 2], U. Klarmann-Schulz[1, 2]
[1]Bonn, [2]Bonn-Cologne, [3]Koeln, [4]Wrocł aw, [5]St. Louis, [6]Hamburg, [7]Kumasi, [8]Geneva

P 104
Development and Implementation of medicines for malaria and poverty-related infectious diseases: Next Generation Antimalarial Drugs
G. Mombo-Ngoma[1, 2],[1]Lambarene, [2]Hamburg

P 105
Safety and Tolerability of Artemether-Lumefantrine + Atovaquone-Proguanil Tri-therapy for Treatment of uncomplicated Malaria in Adults and Adolescents in Gabon- ASAAP Project-Pilot Study.
G. Mombo-Ngoma[1, 2, 3], D. G. Okwu[1], W. Ndzebe Ndoumba[1], E. Lorenz[2, 4], C. Wagner[2], A. Jaeger[2], L.-B. Dimessa Mdadinga[1], M. Groger[2], J. Clain[5], O. Maiga-Ascofare[2, 4, 6], C. the ASAAP[2]
[1]Lambarene, [2]Hamburg, [3]Tubingen, [4]Hamburg- Lubeck-Borstel-Riems, [5]Paris, [6]Kumasi

P 106
Update on the development of novel anthelminthics and novel models for preclinical testing
F. Risch[1], A. Ehrens[1], M. Koschel[1], T. Aden[1], M. Fendler[1], U. Klarmann-Schulz[1], T. Becker[1], A. Krome[1], K. G. Wagner[1], H. McSorley[2], K. Mäder[3], A. Schiefer[1], K. Pfarr[1], A. Hoerauf[1], M. P. Hübner[1]
[1]Bonn, [2]Dundee, [3]Halle (Saale)

P 107
Preclinical in vitro characterisation of two MVA vector viruses expressing the fusion and matrix proteins of Nipah virus
G. Kalodimou[1], A. Tscherne[1], S. Veit[1], A. Freudenstein[1], S. Jany[1], C. C. Broder[2], A. Volz[1, 3], G. Sutter[1]
[1]Munich, [2]Bethesda, [3]Hannover

P 108
Immunogenicity of the COVID-19 vaccine candidate MVA-SARS-2-S after short and long-term prime-boost schedules in pre-clinical vaccination
G. Kalodimou[1], A. Tscherne[1], J. H. Schwarz[1], L. Limpinsel[1], C. Rohde[2, 3], S. Halwe[2, 3], V. Krähling[2, 3], A. Kupke[2, 3], S. Jany[1], A. Freudenstein[1], S. Becker[2, 3], A. Volz[1, 4], G. Sutter[1]
[1]Munich, [2]Marburg, [3]Gießen-Marburg-Langen, [4]Hannover



P 109
Soaking of Ebola virus VP40 crystals with small molecules paves the way for rational drug design using in silico methods
A.-D. Werner[1], M. G. Papadopoulos[1], L. Laube[1], M. J. Norris[2], M. Daude[1], A. Heine[1], G. Klebe[1], E. Ollmann Saphire[1], W. Diederich[1], P. Kolb[1], S. Becker[1]
[1]Marburg, [2]La Jolla

P 110
Oxidative stress in insecticide resistant Anopheles gambiae mosquitoes and impact on Plasmodium spp. development
P. Hoerner, R. Logan, A. Böhmert, M. Ebeling, N. Vallon, V. Ingham
Heidelberg

P 111
Lassa virus persistence in its natural reservoir host, Mastomys natalensis
C. Hoffmann, E. Pallasch, S. Wurr, S. Bockholt, N. Burckhardt, J. Müller, S. Günther, L. Oestereich
Hamburg

P 112
The O-150 LAMP assay provides a new field applicable tool for identifying Onchocerca volvulus infections from human skin biopsies and blackfly vectors
K. Pfarr[1], R. A. Abong[2], G. N. Amambo[2], A. J. Njouendou[2], F. N. Nietcho[2], A. A. Hamidl[2], M. Ritter[1], A. A. Beng[2], M. E. Esum[2], J. Fru-Cho[2], F. F. Fombad[2], P. I. Enyong[2], Z. Li[3], C. Carlow[3], A. Hoerauf[1], S. Wanji[2]
[1]Bonn, [2]Buea, [3]Ipswich

P 113
Corallopyronin A: Successful non-GLP toxicity tests and advances in large-scale production support continued development to first in human trials
A. Schiefer[1], M. Stadler[2], K. Wagner[1], R. Jansen[2], A. Krome[1], T. Becker[1], S. Kehraus[1], M. P. Hübner[1], A. Ehrens[1], M. Grosse[2], G. M. König[1], S. Alt[2], R. Müller[3], T. Hesterkamp[2], K. Pfarr[1], A. Hoerauf[1]
[1]Bonn, [2]Braunschweig, [3]Saarbruecken

P 114
Identification and validation of immunodominant Lassa virus CD8 T cell epitope
O. Blake[1], J. Müller[1], Y. Ighodalo[2], A. Thielebein[1], A. Taju[2], D. Asogun[2], D. Adomeh[2], M. Pahlmann[1], S. Duraffour[1], D. Wozniak[3], L. Unrau[1], E. Pallasch[1], S. Günther[1], E. Ogbaini-Emovon[2], L. Oestereich[1]
[1]Hamburg, [2]Irrua, [3]Berlin

P 115
The Role of Non-Retroviral Integrated RNA Virus Elements of Ebola Virus in Immune Tolerance
C. Henkel
Hamburg

P 116
The Antiviral Compound Testing Platform (ACTP) and its application to identify broad-spectrum antivirals
H. Kim[1], S. Becker[2], C. Drosten[3], G. Gabriel[4], B. M. Kümmerer[5], C. Meier[6], S. Pleschka[7], A. von Brunn[8], J. Ziebuhr[7], R. Bartenschlager[1]
[1]Heidelberg, [2]Marburg, [3]Berlin, [4]Hannover, [5]Bonn, [6]Hamburg, [7]Gießen, [8]München

P 117
Increase in neutralizing antibodies and induction of epitope-specific humoral immunity after booster vaccination with vaccine candidate MVA-MERS-S against the Middle East Respiratory Syndrome
A. Fathi[1, 2], C. Dahlke[1, 2], V. Krähling[3, 4], A. Kupke[3, 4], N. M. A. Okba[5], M. Raadsen[5], J. Heidepriem[6], M. A. Müller[7], G. Paris[6], S. Lassen[1, 2], M. Klüver[3, 4], A. Volz[8], T. Koch[1, 2], M. L. Ly[1, 2], M. Friedrich[1, 2], R. Fux[9], A. Tscherne[9], G. Kalodimou[9], S. Schmiedel[1, 2], V. M. Corman[7], T. Hesterkamp[10], C. Drosten[7], F. Löffler[6], B. L. Haagmans[5], G. Sutter[9], S. Becker[3, 4], M. M. Addo[1, 2]
[1]Hamburg, [2]Hamburg-Lübeck-Borstel-Riems, [3]Marburg, [4]Gießen-Marburg-Langen, [5]Rotterdam, [6]Potsdam, [7]Berlin, [8]Hannover, [9]Munich, [10]Braunschweig

P 118
Trans-kingdom cross talk: Investigating interactions between Orientia tsutsugamushi and influenza virus
S. U. Sapre, E. Friebertshäuser, M. Matrosovich, C. Keller
Marburg

P 119
Multi-level inhibition of coronavirus replication by chemical ER stress
M. S. Shaban[1], C. Müller[1], C. Mayr-Buro[1], H. Weiser[1], J. Meier-Soelch[1], B. V. Albert[1], A. Weber[1], U. Linne[2], T. Hain[1], N. Karl[1], N. Hofmann[1], S. Becker[2], S. Herold[1], M. L. Schmitz[1], J. Ziebuhr[1], M. Kracht[1]
[1]Giessen, [2]Marburg

P 120
Mode of action and genetic engineering of Uridyl Peptide Antibiotics
P.-H. Koutsandrea, R. Sonnengruen, H. Gross, B. Gust
Tuebingen

P 121
Besides strong inflammation, severe COVID-19 is determined by endothelial dysfunction and dysregulated cytokine networks
L. Ruhl[1], I. Pink[1], J. Kuehne[1], K. Beushausen[1], J. Keil[1], S. Christoph[1], A. Sauer[1], L. Boblitz[1], J. Schmidt[1], S. David[2], H.-M. Jäck[3], E. Roth[3], M. Cornberg[1], T. F. Schulz[1], T. Welte[1], M. Höper[1], C. S. Falk[1]
[1]Hannover, [2]Zurich, [3]Erlangen

P 122
User acceptance of and compliance with the eResearch System PIA for epidemiological infectious disease research
J. Ortmann[1], J.-K. Heise[1], C. Frömke[2], I. Janzen[1], Y. Kemmling[1], S. Castell[1]
[1]Brunswick, [2]Hanover



P 123
New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells
N. Leonidou, A. Renz, R. Mostolizadeh, A. Dräger
Tübingen

P 124
Comprehensive pathogen screening of urban rats
C. Mehl[1], J. Panajotov[1], K. Schmidt[2], D. Höper[1], S. Niendorf[3], S. Böttcher[3], K. Schaufler[4], A. Esther[5], T. Eisenberg[6], A. F. Mohammed[6], E. Schmidt[7], C.-T. Bock[3], D. Hoffmann[1], S. Drewes[1], M. Beer[1], M. Pfeffer[7], R. G. Ulrich[1]
[1]Greifswald-Insel Riems, [2]Heidelberg, [3]Berlin, [4]Greifswald, [5]Münster, [6]Gießen, [7]Leipzig

P 125
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
D. Junker[1], A. Dulovic[1], M. Becker[1], M. Bitzer[2], S. Göpel[2], N. Schneiderhan-Marra[1]
[1]Reutlingen, [2]Tübingen

P 126
Feasibility and Diagnostic Accuracy of Saliva-Based SARS-CoV-2 Screening in Educational Settings and Children Aged <12 Years
M. Hoch[1], S. Vogel[1], U. Eberle[2], L. Kolberg[1], V. Gruenthaler[1], V. Fingerle[2], N. Ackermann[2], A. Sing[2], B. Liebl[1], J. Huebner[1], S. Kuttiadan[1], A. Rack-Hoch[1], M. Meyer-Buehn[1], T. Schober[1], U. von Both[1]
[1]Munich, [2]Oberschleissheim

P 127
Relevance of BET Family Proteins and BET-Inhibitors in SARS-CoV-2 Infection and Pathogenicity
M. Hohner[1], N. Ruetalo[1], D. Hu[1], R. Businger[1], U. Lauer[1], F. Ruoff[2], M. Templin[2], M. Schindler[1]
[1]Tübingen, [2]Reutlingen

P 128
Inequalities and peripherality as determinants of geographical variability in COVID-19 vaccination coverage in Poland
A. Jarynowski[1, 2], M. Wójta-Kempa[2], V. Belik[1]
[1]Berlin, [2]Wroclaw

P 129
Interference of mosquito-borne viruses by an insect specific virus: a novel control strategy
M. Altinli[1], M. Leggewie[1], J. Schulze[1], J. Brink[1], S. Junglen[2], E. Schnettler[1]
[1]Hamburg, [2]Berlin

P 130
Identification of primary target cells of Lassa virus in vivo
L. Unrau[1], O. Blake[1], D. Wozniak[1, 2], E. Pallasch[1], S. Günther[1], L. Oestereich[1]
[1]Hamburg, [2]Berlin

P 131
Development of a novel point-of-care diagnostic test for schistosomiasis
Y. Hamway[1], S. Abdellatif[1, 2], C. Prazeres da Costa[1]
[1]Munich, [2]Linz

P 132
Pharmacokinetic Properties of the Irrua-Ribavirin-Regimen in the Treatment of Lassa Fever in Nigeria – a Prospective Observational Study
M. Groger[1], C. Erameh[2], O. Edeawe[2], C. Kleist[1], S. Duraffour[1], F. Babatunde[2], J. Nwatuzor[2], Y. Ighodalo[2], L. Oestereich[1], J. Hinzmann[1], J. Müller[1], M. Hinrichs[1], M. Pahlmann[1], C. Wagner[1], F. Sarpong[1], T. Koch[1], G. Eifediyi[2], E. Ogbaini-Emovon[2], S. Okogbenin[2], S. Wicha[1], S. Günther[1], M. Ramharter[1], P. Akhideno[2]
[1]Hamburg, [2]Irrua

P 133
Differences in Humoral Response to SARS-CoV-2 Vaccination in Lung and Heart Transplant Recipients - Specified for IgG response to different Spike Protein Domains -
J. Sauer[1], K. Beushausen[1], J. Keil[1], L. Ruhl[1], J. F. Kühne[1], M. Schael[1], J. Gottlieb[1], T. Welte[1], A. Haverich[1], C. S. Falk[1, 2]
[1]Hannover, [2]Hannover - Braunschweig

P 134
Serum biomarker and clinical analysis reveal an early fibroproliferative signature associated with COVID-19 end organ damage
H. Maaß[1], M. Ynga Durand[1], M. Zoodsma[2], M. Miloševi[3], F. Krstanovi[3], M. Pribanic Matesic[3], S. Jonji[3], I. Brizi[3], A. Šusti[3], Y. Li[2], A. Proti[3], L. Cicin-Sain[1, 2]
[1]Braunschweig, [2]Hannover, [3]Rijeka

P 135
TB22 – a 22 gene signature for diagnosing TB
M. Reimann[1, 2, 3], J. Heyckendorf[1, 2, 3], S. Marwitz[1, 4], DZIF-TB cohort study group, T. Goldmann[1, 4], C. Lange[1, 2, 3, 5]
[1]Borstel/Sülfeld, [2]Braunschweig, [3]Lübeck, [4]Gießen, [5]Solna

P 136
Machine Learning Prediction of Malaria Vaccine Efficacy Based on Antibody Profiles After Immunization and Before and After CHMI
J. Wistuba-Hamprecht[1], B. Reuter[1], R. Fendel[1, 2], J. J. Campo[3], S. L. Hoffman[4], P. L. Felgner[3], P. G. Kremsner[1, 2], B. Mordmüller[1, 2, 5], N. Pfeifer[1]
[1]Tübingen, [2]Lambaréné, [3]Irvine, CA, [4]Rockville, [5]Nijmegen

P 137
Intention-to-treat analysis: how to deal with missing values in onchocerciasis clinical trials with one-time-measurement outcomes
B. Grützmacher[1], S. Specht[2], A. Y. Debrah[3], M. Schmid[1], A. Hoerauf[1], U. Klarmann-Schulz[1]
[1]Bonn, [2]Geneva, [3]Kumasi



P 138
A broadly acting flavivirus capsid inhibitor - characterization and optimization of C10
N. Ruetalo[1], J. Dürrwald[1], L. Wiltzer-Bach[1], M. Benz[1], A. Schöbel[2], E. Herker[2], J. Müller[3], J. Münch[3], B. Schnierle[4], R. König[4], V. von Messling[4], M. V. Gondim[5], K. Schorpp[5], K. Hadian[5], S. Yang[6], D. A. Jans[6], M. Günther[1], S. Laufer[1], M. Schindler[1]
[1]Tübingen, [2]Marburg, [3]Ulm, [4]Langen, [5]Neuherberg, [6]Melbourne

P 139
COVID-19 profile in Africa: Clinical course of COVID-19 in African setting and transmission pattern within households of COVID-19 patients
Y. Honkpehedji[1, 2, 3], J.-R. Edoa[1], A. Garcia Naranjo[1], R. Adegbite[1, 4], J. Zinsou[1, 2], C. Mbavu[2], E. N'noh Dansou[1], M. Akotet-Bouyou[5], B. Lell[1, 6], M. Yazdanbakhsh[3], A. Adegnika[1, 2, 3], on behalf of the AIDCO consortium
[1]Lambarene, [2]Tübingen, [3]Leiden, [4]Amsterdam, [5]Libreville, [6]Vienna

P 140
Optimized adaptive T cell immunity upon SARS-CoV-2 breakthrough versus none-breakthrough infections?
M. I.M. Ahmed[1, 2], P. Diepers[1], C. Janke[1], M. Plank[1], T. M. Eser[1, 2], R. Rubio-Acero[1], A. Fuchs[1], O. Baranov[1, 2], N. Castelletti[1], B. Bauer[1], D. Wang[1], M. Prelog[3], J. G. Liese[4], C. Reinkemeyer[1], M. Hoelscher[1, 2], P. Steininger[5], K. Überla[5], A. Wieser[1, 2], C. Geldmacher[1, 2], on behalf of the CoVaKo study group
[1]Munich, [2]Münich, [3]Würzburg, [4]Wuerzburg, [5]Erlangen

P 141
SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients
G. Schaub, D. Ruether, P. Duengelhoef, F. Haag, T. Brehm, A. Hoffmann, A. Fathi, M. Wehmeyer, J. Jahnke-Triankowski, L. Fischer, M. Addo, M. Lütgehetmann, A. Lohse, J. Schulze zur Wiesch, M. Sterneck
Hamburg

P 142
Microfluidic impedance cytometry for complete blood count and malaria diagnostics
P. Jain[1], U. Abbasi[1], S. Subramanian[2], P. G. Kremsner[3, 4], T. P. Velavan[3, 5]
[1]Bangalore, [2]Ammerbuch, [3]Tübingen, [4]Lambaréné, [5]Hanoi

P 143
In vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
A. Kreidenweiss
Tübingen

P 144
Real-time field sequencing establishment in Guinea, 2021: unravelling the molecular origin of Ebola virus resurgence and Marburg virus disease emergence
F. R. Koundouno[1, 2], L. E. Kafetzopoulou[1, 3], J. Hinzmann[1], Y. Sidibé[2], A. Renevey[1], K. Ifono[2], E. V. Nelson[1], G. Annibaldis[1], B. Soropogui[2], P. Lemey[3], S. Günther[1], N. Magassouba[2], S. Duraffour[1]
[1]Hamburg, [2]Conakry, [3]Leuven

P 145
Early T cell mediated SARS-CoV-2 control in the upper airways reduces systemic inflammation
T. M. Eser[1, 2], M. Huth[3, 4], O. Baranov[1, 2], M. I. Ahmed[1, 2], F. Deák[1, 2], K. Held[1, 2], K. Pekayvaz[1], A. Leuniger[1], L. Nicolai[1], R. Rubio-Acero[1], K. Puchinger[1], L. Obrich[1, 2], K. Vanshylla[5], F. Klein[5], A. Wieser[1, 2], M. Hölscher[1, 2], I. Kroidl[1, 2], J. Hasenauer[3, 4], C. Geldmacher[1, 2]
[1]Munich, [2]Partner Site Munich, [3]Neuherberg, [4]Bonn, [5]Cologne

P 146
Breadth and Specificity of the SARS-CoV-2 Non-Structural-Protein 12 (NSP12) specific CD4+ T-cell responses of acute and resolved COVID-19 patients
T. Westphal[1, 2], L. Cords[1], H. Karsten[1], M. Knapp[1], S. Schulte[1], L. Hermanussen[1], M. Mader[1], S. Pischke[1], R. Woost[1], M. Lütgehetmann[1], W. Kwok[3], J. Sidney[4], J. Schulze zur Wiesch[1, 2]
[1]Hamburg-Eppendorf, [2]Hamburg-Lübeck-Borstel-Riems, [3]Seattle, [4]La Jolla

P 147
Cancelled

P 148
SARS-CoV-2 antibody detection in saliva of children in Tübingen – The Coro-Buddy study
C. Heinzel[1], Y. T. Pinilla[1], J. Held[1, 2, 3], R. Fendel[1, 2, 3], A. Kreidenweiss[1, 2, 3]
[1]Tübingen, [2]Partner Site Tübingen, [3]Lambaréné

P 149
A mosquito-transmittable blood stage-attenuated rodent malaria parasite for experimental vaccination – P. berghei
A. G. Abdelrahim, L. Keiber, X. Zheng, M. Jäcklin, L. Zechel, F. Hentzschel, J. Sattler, F. Frischknecht
Heidelberg

P 150
Tetherin suppresses the release of SARS-CoV-2 spike protein-containing virosomes and is downregulated by the viral spike protein
E. Hagelauer, D. Hu, S. Stopper, M. Schindler
Tübingen

P 151
Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic Gabonese adults – A randomized, double-blind, placebo-controlled trial
D. Ekoka Mbassi[1, 2], G. Mombo-Ngoma[1, 2], J. Held[3], D. G. Okwu[2], W. Ndzebe Ndoumba[2], L. C. Kalkman[2], F. A. Ekoka Mbassi[1, 2], L. Pessanha de Carvalho[3], J. Inoue[3], M. Akinosho[2], L. B. Dimessa Mbadinga Weyat[2], E. K. Yovo[2], B. Mordmüller[3, 4], A. A. Adegnika[2, 3], M. Ramharter[1, 2, 5], R. Zoleko Manego[1, 2, 3]
[1]Hamburg, [2]Lambaréné, [3]Tübingen, [4]Nijmegen, [5]Partner Site Hamburg-Borstel-Lübeck-Riems

P 152
Corallopyronin A preclinical development: Efficacy in reducing Wolbachia and adult worms in the Litomosoides sigmodontis rodent model
A. Ehrens[1], A. Schiefer[1], M. Stadler[2], K. Wagner[1], A. Krome[1], T. Becker[1], S. Kehraus[1], M. Große[2], T. Hesterkamp[2], A. Hoerauf[1], K. Pfarr[1], M. Hübner[1]
[1]Bonn, [2]Braunschweig



P 153
The hamster model of severe COVID-19 indicates differential efficacy of authorized vaccines in the absence of immunopathogenesis
A. Ebenig, M. V. Lange, R. Plesker, C. Kruip, T. Maier, M. Mühlebach
Langen

P 154
Protective effect of Ascaris lumbricoides infection on malaria recurrence among children and young adults living in endemic rural areas of Gabon
J. C. Dejon Agobé[1, 2, 3], J. R. Edoa[1, 2, 3], Y. J. Honkpehedji[1, 3, 4], J. F. Zinsou[1, 3], B. R. Adégbitè[1, 2, 3], T. G. Woldearegai[3], B. Mordmüller[3, 5], A. A. Adegnika[1, 3]
[1]Lambaréné, [2]Amsterdam, [3]Tübingen, [4]Leiden, [5]Nijmegen

P 155
Host-pathogen Co-evolution Shapes Susceptibility To Infection With M. tuberculosis
M. Groeschel[1], R. Diel[2], P. Kouw[3], V. Escuyer[4], K. Musser[4], L. Trieu[5], J. Meissner[5], D. van Soolingen[3], S. Niemann[6], S. Ahuja[5], M. Farhat[1]
[1]Boston, [2]Kiel, [3]Bilthoven, [4]Albany, NY, [5]New York City, [6]Borstel

P 156
Circulating Anodic Antigen as a Diagnostic Marker for Measuring Treatment Success in Urogenital Schistosomiasis - preliminary results from the freeBILy-GAB study in Lambaréné Gabon
J. Gerstenberg[1, 2], Y. J. Honkpehedji[1, 2, 3], J. C. Dejon-Agobe[1, 2, 4], R. Rakotozandrindrainy[5], R. A. Rakotoarivelo[6], T. Rasamoelina[5], E. Sicuri[7], N. G. Schwarz[8], P. L. A. M. Corstjens[3], P. T. Hoekstra[3], G. J. van Dam[3], A. Kreidenweiss[1, 3], A. A. Adegnika[1, 2, 3]
[1]Tübingen, [2]Lambaréné, [3]Leiden, [4]Amsterdam, [5]Antananarivo, [6]Fianaranstoa, [7]Barcelona, [8]Hamburg

P 157
Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection
I. Kuznetsova[1], L. Sauerhering[2], A. Kupke[2], L. Meier[2], S. Halwe[2], C. Rohde[2], J. Schmidt[2], R. E. Morty[1], O. Danov[3], A. Braun[3], I. Vadász[1], S. Becker[2], S. Herold[1]
[1]Gießen, [2]Marburg, [3]Hannover

P 158
Optimized Antigen Enhances Efficacy of Next Generation Measles Vaccine-derived COVID-19 Vaccines
M. Lange, A. Ebenig, A. Auste, S. Muraleedharan, M. Dorn, M. Mühlebach
Langen

P 159
Age-specific Contribution of Contacts to Transmission of SARS-CoV-2 in Germany until June 2021
I. Rodiah[1], P. Vanella[1], A. Kuhlmann[2], M. Harries[1], V. Jaeger[3], W. Bock[4], B. Lange[1]
[1]Braunschweig, [2]Hannover, [3]Muenster, [4]Kaiserslautern

P 160

Monitoring of zoonotic West Nile virus and Usutu virus - two emerging arboviruses circulate in the German bird population

U. Ziegler, P. D. Santos, F. Bergmann, A. Günther, C. M. Holicki, B. Sadeghi, D. Höper, M. Keller, M. Eiden, M. Beer, F. J. Conraths, M. H. Groschup
Greifswald-Insel Riems

P 161

Mediators between Poverty and Malaria Incidence among Children in Ghana: Identifying targets for intervention

S. T. Wafula[1], F. Boateng[2], L. Rautmann[1], A. Ginsbach[1], B. Agyemang[2], W. Loag[1], J. Kettenbeil[1], N. Sarpong[2], R. Krumkamp[1], J. Amuasi[2], O. Maiga-Ascofaré[1], E. Mertens[1], N. Struck[1], J. May[1], E. Lorenz[1, 3], J. Brinkel[1], D. I. Puradiredja[1]
[1]Hamburg, [2]Kumasi, [3]Mainz

P 162

Stabilized SARS-CoV-2 spike antigen enhances vaccinia virus MVA vector vaccine immunogenicity and protective capacity

C. Meyer zu Natrup[1], A. Tscherne[2], C. Dahlke[3, 4], M. Ciurkiewicz[1], D.-L. Shin[1], A. Fathi[3, 4], C. Rohde[5, 6], G. Kalodimou[2], S. Halwe[5], L. Limpinsel[2], M. Klug[7], M. Esen[7], N. Schneiderhan-Marra[8], A. Dulovic[7], A. Kupke[5, 6], K. Brosinski[2], S. Clever[1], L.-M. Schünemann[1], F. Armando[1], L. Mayer[3, 4], M. Weskamm[3, 4], S. Jany[2], A. Freudenstein[2], T. Tuchel[1], W. Baumgärtner[1], P. Kremsner[7, 9], R. Fendel[7], M. M. Addo[3, 4], S. Becker[5, 6], G. Sutter[2], A. Volz[1]
[1]Hanover, [2]Munich, [3]Hamburg, [4]Hamburg-Lübeck-Borstel-Riems, [5]Marburg, [6]Gießen-Marburg-Langen, [7]Tübingen, [8]Reutlingen, [9]Lambarene

P 163

The TNF family member LIGHT drives alveolar macrophage death upon influenza infection enabling the establishment of secondary bacterial pneumonia

C. Malainou[1], C. Peteranderl[1], U. Matt[1], A. I. Vazquez-Armendariz[1], J. Better[1], S. Günther[2], M. Looso[2], H. Schultheis[2], J. Hoppe[3], T. Firsching[3], A. Gruber[3], S. Herold[1]
[1]Giessen, [2]Bad Nauheim, [3]Berlin

P 164

PAVON and the challenges of P. vivax malaria in sub-Saharan Africa: Providing the evidence and skills set towards malaria elimination

I. Quaye
Accra

P 165

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralization immunity to all variants of concern

A. Priller[1], P. R. Wratil[1], M. Stern[1], N. Körber[1], T. Bauer[1], S. Yazici[1], C. Christa[1], S. Jeske[1], A. Willmann[1], K. Tinnefeld[1], H. Mijocevic[1], J. Wettengel[1], D. Hoffmann[1], N. Graf[1], C.-C. Cheng[1], E. Vogel[1], H. Wintersteller[1], M. Feuerherd[1], M. Gerhard[1], O. Zelger[1], H. Roggendorf[1], M. Halle[1], J. Erber[1], P. Lingor[1], G. Almanzar[2], G. Lupoli[1], M. Albanese[1], E. Mejías-Pérez[1], S. Bauernfried[1], M. Vu[1], M. Muenchhoff[1], C. Dächert[1], S. Krebs[1], V. Fingerle[3], A. Graf[1], P. Steininger[4], H. Blum[1], V. Hornung[1], B. Liebl[3], K. Überla[4], M. Prelog[2], C. Winter[1], J. Ruland[1], O. Keppler[1], P. A. Knolle[1], U. Protzer[1]
[1]Munich, [2]Würzburg, [3]Oberschleißheim, [4]Erlangen



P 166

Early risk assessment among household contacts of confirmed Mycobacterium tuberculosis cases by conventional and novel diagnostics (ERASE-TB)

U. Panzner[1], D. Banze[2], E. Marambire[3], C. Nhamuave[2], A. Mfinanga[4], H. Mwambola[4], C. Khosa[2], N. E. Ntinginya[4], C. Geldmacher[1], M. Hölscher[1], K. Held[1], K. Kranzer[1, 3, 5], N. Heinrich[1]
[1]Munich, [2]Marracuene, [3]Harare, [4]Mbeya, [5]London

P 167

Dissecting mechanisms of SARS-CoV-2 immune control in the upper airways: Harnessing the benefits of public single cell RNA sequencing data sets

O. Baranov, T. M. Eser, K. Held, M. Hoelscher, C. Talavera-Lopez, C. Geldmacher
Munich

P 168

Infection and transmission risks in schools and contribution to the COVID-19 pandemic in Germany – a retrospective observational study using nation-wide and regional health and education agency notification data

T. Heinsohn[1], B. Lange[1], P. Vanella[1, 2, 3], I. Rodiah[1], S. Glöckner[1], A. Joachim[4], D. Becker[5], T. Brändle[6], S. Dhein[7], S. Ehehalt[8], M. Fries[4], A. Galante-Gottschalk[8], S. Jehnichen[5], S. Kolkmann[7], A. Kossow[4, 9], M. Hellmich[4], J. Dötsch[4], G. Krause[1, 3]
[1]Braunschweig, [2]Rostock, [3]Hannover, [4]Cologne, [5]Gottmadingen, [6]Hamburg, [7]Altenburg, [8]Stuttgart, [9]Muenster

P 169

Identification of genetic variants and expression quantitative trait loci in TB Sequelae

L. Lin[1], K. Hatzikotoulas[2], G. Katsoula[2], O. Baranov[1], L. Rogers[1], J. Sutherland[3], N. E. Ntinginya[4], C. Khosa[5], M. Rassool[6], S. Charalambous[6], M. Hölscher[1], C. Geldmacher[1], E. Zeggini[2], A. Rachow[1], K. Held[1]
[1]Munich, [2]Neuherberg, [3]Fajara, [4]Mbeya, [5]Marracuene, [6]Johannesburg

P 170

Assessment of malaria transmission intensity and insecticide resistance mechanisms in three rural areas of the Moyen Ogooué Province of Gabon

S. T. Boussougou-Sambe[1, 2], T. G. Woldearegai[2], A. G. Doumba-Ndalembouly[1], B. Ngossanga[1], R. Beh Mba[1], R. J. Edoa[1], J. F. Zinsou[1, 3], Y. J. Honkpehedji[1, 3], U. Ateba Ngoa[1], J. C. Dejon-Agobé[1, 4], S. Borrmann[1, 2], P. G. Kremsner[1, 2], B. Mordmüller[1, 2, 5], A. A. Adegnika[1, 2, 6]
[1]Lambaréné, [2]Tübingen, [3]Leiden, [4]Amsterdam, [5]Nijmegen, [6]Cotonou

P 171

Platform for transcriptomic analyses of pathogen-specific T cells and other low-frequency cell types

D. Wang[1], L. Rogers[1], M. I. M. Ahmed[1], T. M. Eser[1], I. Andrä[1], W. Mbuya[2], S. Rüger[1], M. Schiemann[1], J. Roider[1], A. Kroidl[1], M. Hölscher[1], E. Beltrán[1], C. Geldmacher[1], K. Held[1]
[1]Munich, [2]Mbeya

P 172

Finding new drug combinations to fight Tuberculosis – Bioanalytical tools combined with computational analysis

A.-C. Neumann-Cip[1], A. Burger[1], I. Assum[1, 2], M. Menden[1, 2], M. Hoelscher[1], A. Wieser[1]
[1]Munich, [2]Neuherberg

P 173
Characterization of antibody and T-cell response after second COVID-19 booster vaccination
K. Grikscheit[1], Z. Ghodratian[1], H. Rabenau[1], M. Widera[1], A. Wilhelm[1], T. Toptan Grabmair[1], S. Hoehl[1], E. Layer[1], F. Helfritz[1], S. Ciesek[1, 2]
[1]Frankfurt am Main, [2]External partner site Frankfurt

P 174
Multi-Drug Combination-Therapies to Prevent the Development of Drug ResistancePhase II Controlled Clinical Trial Assessing Candidate Regimens of Multiple-Antimalarial Combinations for the Treatment of Uncomplicated Malaria in Africa. MultiMal-Study
J. C. D. Agobé[1], O. Maiga-Ascofare[2, 3], C. Pfaffendorf[3], S. Wicha[3], A. A. Adegnika[1, 4], M. Ramharter[3], J. Mischlinger[3], MultiMal Consortium
[1]Lambaréné, [2]Kumasi, [3]Hamburg, [4]Tübingen

P 175
Characterization of the first reported cases of SARS-CoV-2 infections with Variant of Concern Omicron in Germany
C. Christa[1], A. Priller[1], E. Vogel[1], M. Vu[1], P. Marmorstein[1], S. Yazici[1], G. Wilkens[1], A. Willmann[1], S. Jeske[1], P. R. Wratil[1, 2], M. Stern[1], K. Tinnefeld[1], N. Körber[1], T. Bauer[1, 2], B. Liebl[3], O. T. Keppler[1, 2], P. A. Knolle[1, 2], U. Protzer[1, 2]
[1]Munich, [2]Munich partner site, [3]Oberschleißheim

P 176
Adapting face mask sampling to a pediatric setting – A laboratory report
L. Meiwes[1, 2], I. Kontsevaya[1, 2, 3], Q. Dlamini[4], G. Mtetwa[4], A. Kay[4, 5], A. DiNardo[5], C. M. Williams[6], M. R. Barer[6], A. M. Mandalakas[5], C. Lange[1, 2, 5]
[1]Borstel, [2]Lübeck, [3]London, [4]Mbabane, [5]Houston, [6]Leicester

P 177
The DZIF EX-TB cohort - characteristics of patients with extrapulmonary tuberculosis in Germany
M. Feldmann[1, 2], S. Rohr[1], S. Winter[1], M. Stecher[1, 2], J.-J. Vehreschild[1, 2], C. Lehmann[1, 2], G. Plum[1], S. Knez[1], E. Pracht[1], A. C. Kretschmer[1], C. Horn[1], M. Augustin[1, 2], V. Brandes[1], L. Biehl[1, 2], P. Schommers[1, 2], P. Stephany[1], G. Fätkenheuer[1, 2], J. Rybniker[1, 2], I. Suárez*[1, 2]*
[1]Cologne, [2]Bonn-Cologne

P 178
Wie gut schützen COVID-19-Impfstoffe vor schwerer COVID-19-Erkrankung? Zwischenanalysen einer bundesweiten krankenhausbasierten Fall-Kontroll-Studie
A. Stoliaroff-Pépin[1], C. Peine[1], T. Herath[1], J. Lachmann[1], A. Dörre[1], A. Nitsche[1], J. Michel[1], M. Grossegesse[1], N. Hofmann[1], T. Rinner[1], T. Meyer[1], B. Dorner[1], D. Stern[1], F. Treindl[1], S. Hein[2], L. Werel[2], E. Hildt[2], D. Oberle[2], S. Gläser[1], H. Schühlen[1], C. Isner[1], A. Peric[1], A. Ghouzi[3], M. Burkert[4], A. Reichardt[1], M. Janneck[4], G. Lock[4], O. Wichmann[1], T. Harder[1]
[1]Berlin, [2]Langen, [3]Düsseldorf, [4]Hamburg

P 179
Recombinant anti-Bunyavirus Vaccine Candidates Based on Live-attenuated Measles Virus
M. R. Gadalla, C. Hörner, A. Fiedler, F. Haas, M. D. Mühlebach
Langen(Hessen)



P 180
Gewebesammlung für die Pandemie-Forschung – Das COVID-19 Autopsie- und Bioproben-Register Baden-Württemberg
I. M. Klein, L. Hartmann, L. M. Domke, P. Schirmacher
Heidelberg

P 181
Preclinical immunogenicity of MVA-SARS-2-S candidate vaccines in heterologous prime-boost immunizations using wild-type and variant SARS-CoV-2 spike antigens
A. Tscherne[1], G. Kalodimou[1], C. Rohde[2], A. Kupke[2], S. Jany[1], A. Freudenstein[1], J. H. Schwarz[1], L. Limpinsel[1], K. Brosinski[1], S. Becker[2], A. Volz[1, 3], G. Sutter[1]
[1]Munich, [2]Marburg, [3]Hannover

P 182
Identifying SARS-CoV-2 host factors from large scale perturbation screens employing machine learning
A. Vera-Guapi[1], T. Beder[2], M. Oswald[1], H. Erfle[3], T. Toptan[4], R. Koenig[1]
[1]Jena, [2]Kiel, [3]Heidelberg, [4]60596 Frankfurt am Main

P 183
Whole genome analysis provides evidence for the existence of two sympatric Mansonella species: Mansonella perstans and Mansonella sp. "DEUX"
M. Rodi[1], C. Gross[1], T. Lucas Sandri[1], L. Berner[1], E. Kocak[1], S. Agnandji[1, 2], A. Kreidenweiss[1, 2], S. Ossowski[1], J. Held[1, 2]
[1]Tübingen, [2]Lambaréné

P 184
Increasing immune activation in patients with advanced stage filarial lymphedema
S. Horn[1], A. Feichtner[1], A. Ngenya[2], M. Demetrius[2], Y. Mgaya[2], J. Osei-Mensah[3], V. S. Opoku[3], U. Klarmann-Schulz[4], J. Kuehlwein[4], M. Ritter[4], A. Hoerauf[4], M. Hoelscher[1], A. Kilinga[2], A. Y. Debrah[3], I. Kroidl[1]
[1]Munich, [2]Dar es Salaam, [3]Kumasi, [4]Bonn

P 185
High-resolution analysis of individual spike peptide-specific CD4⁺ T-cell responses in vaccine recipients and COVID-19 patients
H. Karsten, L. Cords, T. Westphal, M. Knapp, T. T. Brehm, R. Woost, C. Ackermann, M. Wittner, M. M. Addo, J. Schulze zur Wiesch
Hamburg

P186
Steps towards Phase I – drug substance and drug product development of Corallopyronin A
M. Große [1], K. Wagner [2], T. Becker [2], A. Krome [2], R. Jansen [1], D. Pogorevc [3], A. Schiefer[2], S. Alt [1], R. Müller [3], T. Hesterkamp [1], K. Pfarr [2], M. Stadler [1], A. Hoerauf [2]
[1] Braunschweig, [2] Bonn, [3]Saarbrücken

ANTIMICROBIAL RESISTANCE

P 187
Evaluation of Bacteriophages targeting Escherichia coli including Extended-Spectrum Beta-Lactamase (ESBL)- Producing Isolates – First Results of the IDEAL-EC study
A. Y. Classen[1, 2], M. J. Vehreschild[1, 3], H. Seifert[1], A. Hamprecht[1, 4], P. G. Higgins[1], I. H. E. Korf[2], S. V. Walker[1], L. Biehl[1], J. J. Vehreschild[1, 3], J. Wittmann[2], C. Rohde[2]
[1]Cologne, [2]Braunschweig, [3]Frankfurt, [4]Oldenburg

P 188
A stable isotope-labeled marker amino acid enables quantification of the antimicrobial peptide Pep19-2.5
S. Wohlfart[1], M. Kilian[1], P. Storck[1], T. Gutsmann[2], K. Brandenburg[3], W. Mier[1]
[1]Heidelberg, [2]Borstel, [3]Borsterl

P 189
INCATE: Supporting innovators to fight drug-resistant infections
S. Alt[1], F. Kloß[2], D. Haggstrom[3], H. Kessmann[3]
[1]Braunschweig, [2]Jena, [3]Basel

P 190
Mycobacterium tuberculosis complex bacteria (MTBC) adaptation to antibiotics: Evolution informed tuberculosis treatments
T. Walz, L. Sonnenkalb, S. Niemann
Borstel

P 191
IFN-ß is downregulated by cyclophilin and SARS-CoV-2 nucleocapsid N protein
P. Li, Y. Ma-Lauer, J. Liu, Y. Ru, B. von Brunn, A. von Brunn
München

P 192
Pharmacokinetic evaluation of FU002 as new treatment option for vancomycin- and linezolid-resistant enterococci
J. Werner[1], F. Umstätter[1], L. Zerlin[1], E. Mühlberg[1], C. Kleist[1], K. D. Klika[1], T. Hertlein[2], C. Domhan[1], S. Zimmermann[1], K. Ohlsen[2], U. Haberkorn[1], W. Mier[1], P. Uhl[1]
[1]Heidelberg, [2]Würzburg

P 193
The Global AMR R&D Hub: Global knowledge centre and driving force for evidence-based AMR advocacy
U. Lamichhane, T. Herfurth, R. Sudbrak, L. A. Ogilvie
Berlin

P 194
Highly Active Daptomycin-Peptide-Conjugates with Ca^{2+}-Independent Mode of Action
F. Umstätter[1], S. Rasheed[2, 3], E. Mühlberg[1], T. Hertlein[4], C. Domhan[1], K. D. Klika[1], C. Kleist[1], J. Werner[1], S. Zimmermann[1], B. Beijer[1], K. Ohlsen[4], U. Haberkorn[1], M. Koch[2], M. Bischoff[5], R. Müller[2, 3], J. Herrmann[2, 3], W. Mier[1], P. Uhl[1]
[1]Heidelberg, [2]Saarbrücken, [3]Braunschweig, [4]Würzburg, [5]Homburg

P 195
Fragment-based carbapenemase inhibitor with bacteriostatic activity
E. Kalfopoulou[1], D. Norman[1], V. Napolitano[1, 2], M. Bostock[1, 2], V. Korotkov[3], M. Sattler[1, 2], M. Brönstrup[3], G. Popowicz[1, 2], H. Meyer[1]
[1]Munich, [2]Neuherberg, [3]Braunschweig

P 196
Novel lead compound discovery for inhibition of Mycobacterium tuberculosis major virulence factor ESX-1
R. Gries, E. van Gumpel, J. Chhen, S. Theobald, M. Dal Molin, J. Rybniker
Cologne

P 197
Prevalence, risk factors and molecular epidemiology of mcr-1-encoding Escherichia coli in patients in Germany
S. Delfani[1], I. Hormel[2], J. Falgenhauer[2], C. Imirzalioglu[2], H. Seifert[3], N. Käding[4], A. Dinkelacker[5], S. Walker[3], G. Rose[6], A. Kola[6], K. Schmauder[5], J. Rupp[4], D. Tobys[3], T. Chakraborty[2], L. Falgenhauer[2]
[1]Khorramabad, [2]Giessen, [3]Cologne, [4]Lübeck, [5]Tuebingen, [6]Berlin

P 198
Corallopyronin A is an effective antibiotic against multi-resistant Neisseria gonorrhoeae
K. Pfarr[1], J. Balthazar[2], J. Edwards[3], S. Acar[1], M. Grosse[4], R. Jansen[4], M. Stadler[4], A. Schiefer[1], T. Hesterkamp[4], A. Hoerauf[1], W. Shafer[2]
[1]Bonn, [2]Atlanta, [3]Columbus, [4]Braunschweig

P 199
Contribution of the RND efflux pump regulatory system AdeRS in susceptibility to biocides in Acinetobacter baumannii
C. Meyer, K. Lucaßen, S. Gerson, K. Xanthopoulou, T. Wille, H. Seifert, P. G. Higgins
Cologne

P 200
Prospective evaluation of targeted next-generation sequencing of Mycobacterium tuberculosis complex strains in routine diagnostics in Germany
D. Nadarajan[1], P. Beckert[1], M. Kuhns[1], C. Utpatel[1], I. Barilar[1], V. Dreyer[1], F. P. Maurer[1, 2], S. Niemann[1]
[1]Borstel, [2]Hamburg

P 201
Development and integration of glycopeptide-resistant-enterococci rapid detection kit into routine clinical care (INTEGRATE)
M. Gonzalez-Rodriguez[1], S. Mertins[1], L. Maus[1], F. Grein[2], S. Rieg[3], P. G. Higgins[1], A. Klimka[1]
[1]Cologne, [2]Bonn, [3]Freiburg

P 202
Strengthening Diagnostic Laboratories in Rural Ghanaian Hospitals – An Integrated Approach to Tackle Antimicrobial Resistance
M. M. Lamshöft[1, 2], C. Wiafe Aketen[3], K. Oppong[3], L. Mawuli Aglanu[3], R. Moirongo[1], W. Loag[1], O. Maiga Ascofaré[1, 2, 3], E. Lorenz[1, 2], J. May[1, 2], D. Eibach[1], D. Dekker[1, 2], J. Amuasi[3]
[1]Hamburg, [2]Hamburg-Lübeck-Borstel-Riems, [3]Kumasi

P 203
Development of an immunochromatographic lateral flow assay to rapidly detect OXA-23-, OXA-40- and OXA-58-mediated carbapenem resistance determinants in Acinetobacter baumannii
S. Mertins[1], P. G. Higgins[1], C. Thunissen[2], Q. Gilleman[2], P. Mertens[2], M. Krönke[1], A. Klimka[1]
[1]Cologne, [2]Gembloux

P 204
High-Dose Second-Line Treatment under Therapeutic Drug Monitoring in two Patients with pre-XDR- and XDR-TB
N. Köhler[1], R. Aarnoutse[2], P. Abel zur Wiesch[3], S. Andres[1], R. A. Bonomo[4], E. Choong[5], F. Clarelli[3], L. Decosterd[5], A. R. DiNardo[6], H.-P. Grobbel[1], J. Heyckendorf[1], D. Hillemann[1], H. Hoffmann[7], B. Kalsdorf[1], C. König[8], M. Kuhns[1], A. Martinecz[3], F. Maurer[1, 8], M. Merker[1], S. Niemann[1], C. A. Peloquin[9], D. Schaub[1], T. Schön[10], D. Schwudke[1], D. Strelec[11], M. Teulen[2], N. Verougstraete[12], A. Verstraete[12], F. Marwitz[1], J. Werngren[13], S. G. Wicha[8], P. Sanchez Carballo[1], C. Lange[1, 6, 14]
[1]Borstel, [2]Nijmegen, [3]Tromsø, [4]Cleveland (Ohio), [5]Lausanne, [6]Houston (Texas), [7]Gauting, [8]Hamburg, [9]Gainesville (Florida), [10]Linköping, [11]Klenovnik, [12]Ghent, [13]Solna, [14]Lübeck

P 205
Workflow for modeling microbial community interactions applied to Dolosigranulum pigrum and Staphylococcus aureus within the human nose
R. Mostolizadeh, M. Glöckler, A. Dräger
Tübingen

P 206
Structure-Based Discovery of Novel Bacterial Sliding Clamp (DnaN) Inhibitors
W. A. M. Elgaher[1], S. Rasheed[1], P. Lukat[2], J. Herrmann[1], S. Jergic[3], N. E. Dixon[3], N. Reiling[4], W. Blankenfeldt[2], R. Müller[1], A. K. H. Hirsch[1]
[1]Saarbrücken, [2]Braunschweig, [3]Wollongong, [4]Borstel

P 207
Bioinformatics tools to guide the discovery of new natural products
M. Adamek, S. Mantri, M. D. Mungan, N. Ziemert
Tübingen

P 208
Genetic landscape of third-generation cephalosporin-resistant and carbapenem-resistant Klebsiella pneumoniae complex upon hospital admission in Germany
K. Xanthopoulou[1], J. Wille[1], S. V. Walker[1], V. Persy[1], C. Imirzalioglu[2], D. Tobys[1], K. Lucaßen[1], H. Seifert[1], P. G. Higgins[1], for the DZIF-R-NET Study Group
[1]Cologne, [2]Giessen



P 209
Multispecies carriage of KPC-2: an outbreak related to the mobilome
K. Xanthopoulou, J. Wille, V. Persy, T. Burgwinkel, K. Lucaßen, J. Zweigner, A. Meißner, H. Seifert, P. G. Higgins
Cologne

P 210
The RNA polymerase inhibitor corallopyronin A has a lower frequency of resistance than rifampicin in Staphylococcus aureus
K. Pfarr[1], J. Balansky[1], C. Szekat[1], T. Aden[1], M. Grosse[2], R. Jansen[2], T. Hesterkamp[2], A. Schiefer[1], M. Stadler[2], A. Hoerauf[1], G. Bierbaum[1]
[1]Bonn, [2]Braunschweig

P 211
C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus
L. Paulowski[1], K. Beckham[2], M. Johansen[3], L. Berneking[2], N. Van[4], Y. Degefu[4], S. Staack[2], F. Vasquez Sotomayor[1, 2], L. Asar[2], H. Rohde[2], B. Aldridge[4], M. Aepfelbacher[2], A. Parret[2, 5], M. Wilmanns[2], L. Kremer[3], K. Combrink[6, 7], F. Maurer[1, 2]
[1]Borstel, [2]Hamburg, [3]Montpellier, [4]Medford, MA, [5]Beerse, [6]Laredo, TX, [7]Bryan, TX

P 212
Cancelled

P 213
Description of epidemiological and genetic characteristics of vancomycin-resistant Enterococcus faecium isolates in a university children's hospital in Germany – 2019 to 2020
I. Trautmannsberger[1], L. Kolberg[1], M. Meyer-Bühn[1], J. Hübner[1], G. Werner[2], R. Weber[2], V. Heselich[1], S. Schröpf[1], U. von Both[1]
[1]Munich, [2]Wernigerode

P 214
Exploring the unexplored - AMR and ABS research in DZIF-CRU, Tübingen
P. Beryl[1], S. Göpel[1], A. Savoldi[1, 2], P. Shamsrizi[1, 3], A. Gorska[2], N. Babu Rajendran[1], K. Schmauder[1], N. Conzelmann[1], S. Eisenbeis[1], E. Tacconelli[1, 2]
[1]Tübingen, [2]Verona, [3]Hamburg

P 215
Carbapenem-resistant Citrobacter spp. as an emerging concern in the hospital-setting: Results from a genome-based regional surveillance study
Y. Yao[1], L. Falgenhauer[1], J. Falgenhauer[1], P. Heinmüller[2], M. Fritzenwanker[1], A. M. Hauri[3], E. Domann[1], T. Chakraborty[1], C. Imirzalioglu[1]
[1]Gießen, [2]Dillenburg, [3]Braunschweig

P 216
First application of the ClinTb antibiotics platform for preclinical research of nanocarrier based drug delivery system
F. Marwitz[1], G. Hädrich[2], K. Besecke[3], M. Furch[3], L. A. Dailey[2], D. Schwudke[1]
[1]Borstel, [2]Vienna, [3]Düsseldorf

P 217
Regulation of lugdunin biosynthesis and transport
L. Reetz, B. Krismer, A. Peschel
Tübingen

P 218
Experimental and bio-informatic determination of mutation rates in highly multi-drug resistant Mycobacterium tuberculosis lineages
E. Rousseau[1], H. Schulenburg[2], T. Wirth[3], M. Merker[1], S. Niemann[1]
[1]Borstel, [2]Kiel, [3]Paris

P 219
Characterization of the novel antimicrobial peptide epilancin A37 from Staphylococcus epidermidis
B. Winnerling[1], J.-S. Puls[1], J. Power[2], D. Brajtenbach[1], A. Krüger[1], U. Kubitschek[1], S. Heilbronner[2], F. Grein[1]
[1]Bonn, [2]Tübingen

P 220
Modified Appelmans protocol for in vitro Klebsiella pneumoniae phage host range expansion
N. Jakob[1], A. Filippov[2], D. Friese[1], B. Swierczewski[2], R. Kevorkian[2], R. Wölfel[1], J. J. Bugert[1]
[1]Munich, [2]Silver Spring, MD

P 221
Development of an in vitro gut model as preclinical test system for decolonization strategies
T. Fließwasser, F. Grein
Bonn

P 222
Resistant Aspergillus fumigatus – a new threat?
M. M. Rüthrich[1], G. Walther[1], S. Hartung[1], O. Kurzai[1, 2], M. von Lilienfeld-Toal[1]
[1]Jena, [2]Würzburg

P 223
THCz: Synthetic small molecules that target the bacterial cell wall precursor lipid II
K. Ludwig[1], E. Reithuber[2], M. Rausch[1], A. Müller[1], F. Grein[1], S. Normark[2], B. Henriques-Normark[2], T. Schneider[1]
[1]Bonn, [2]Stockholm



P 224
Resistance patterns among multidrug-resistant tuberculosis patients in Gabon: Trends-over-time analysis of the national surveillance data and impact of Xpert MTB/RIF and decentralized care on case-finding
B. R. Adegbite[1], J. B. P. Achimi Agbo Abdul[1], A. A. Adegnika[2], M. P. Grobusch[3]
[1]Lamabrene, [2]Tübingen, [3]Amsterdam

P 225
MraY from Pseudomonas aeruginosa is inhibited by uridyl-peptide antibiotics
J.-M. Daniel[1], M. Arts[1], B. Gust[2], H. Groß[2], T. Schneider[1]
[1]Bonn, [2]Tübingen

P 226
Entwicklung eines Anamnese-basierten Algorithmus für das Delabeling von Penicillinallergien bei hospitalisierten Patient:innen
T. Koch, H. Leubner, T. T. Brehm
Hamburg

P 227
Antimicrobial Profile of Acinetobacter spp. from clinical isolates of patients in rural Ghana
C. W. Akenten[1], R. Moirongo[2], M. Lamshöft[2], J. Amuasi[1], J. Ankomah[1], K. Baffour[1], O. M. Ascofaré[1], W. Loag[2], E. Lorenze[2], J. May[2], D. Dekker[2]
[1]Kumasi, [2]Hamburg

P 228
Anwendbarkeit europäischer Leitlinien für komplizierte Zystitiden: Antibiotikaresistenzraten und ihre Auswirkung auf Therapieempfehlungen in einem Krankenhaus der Grund- und Regelversorgung
S. C. Müller[1], C. Eisenbach[2]
[1]Heidelberg, [2]Weinheim

P 229
Influence of human-targeted drugs on virulence factor regulation in EHEC
B. von Armansperg[1], M. Koeppel[1], J. Glaser[1], M. List[1], A. Typas[2], B. Stecher[1]
[1]München, [2]Heidelberg

P 230
Burden of antibiotic resistance among patient populations receiving antibiotic prophylaxis: preliminary results from a systematic review and meta-analysis
M. Rink[1], P. Beryl[1], S. Eisenbeis[1], M. Bitzer[1], E. Tacconelli[1, 2], S. Göpel[1]
[1]Tübingen, [2]Verona

P 231
Staphylococcus capitis isolates from neonatal sepsis and necrotizing enterocolitis specified to resist human intestinal gut immunity and opposing colonizers
L. Kränkel[1], J. N. Hauser[1], J. Power[1], A. Schmidt[1], C. Gille[2], A. Peschel[1], C. Slavetinsky[1]
[1]Tübingen, [2]Heidelberg

POSTERS



P 232
Rapid molecular resistance prediction based on targeted sequencing of stool specimen
V. Dreyer[1], A. Kay[2, 3], D. Sibandze[2, 3, 4], W. Sikhondze[2], Q. Dlamini[2, 3], A. DiNardo[3], G. Mtetwa[2, 3], B. Lukhele[2, 3], D. Vambe[2], C. Lange[1, 3, 5], M. Dlam[4], R. Meija[3], B. Kalsdorf[1, 5, 6], J. Heyckendorf[1, 5], M. Kuhns[1], F. Maurer[1, 7], S. Dlamini[4], G. Maphalala[4], S. Niemann[1], A. Mandalakas[3]
[1]Borstel, [2]Mbabane, [3]Texas, [4]Eswatini, [5]Lübeck, [6]Kiel, [7]Hamburg

P 233
Highly potent small molecule inhibitors of the Staphylococcus aureus toxinhemolysin alpha prevent tissue damage and are active in mouse models of infection
A. Shekhar[1], R. DiLucrezia[2], K. Jerye[1], K. Rox[1], E. Fansa[2], V. Korotkov[1], K. Harmrolfs[1], S. Schmelz[1], P. Lukat[1], W. Blankenfeldt[1], E. Medina[1], U. Bilitewski[1], K. Dinkel[2], M. Brönstrup[1]
[1]Braunschweig, [2]Dortmund

P 234
Darobactin Derivatization – Expanding the Class of Bicyclic BamA Inhibitors
T. Schäberle, Z. Wuisan, N. Böhringer, I. D. Kresna
Giessen

P 235
Impact of Klebsiella pneumoniae outer membrane vesicles on antibiotic resistance
M. Wiegand, P. Starck, L. Pearson, L. Rösser, G. Angelidou, C. Preusser, N. Paczia, B. Schmeck, A. L. Jung
Marburg

P 236
A novel machine learning-based point-score model for differentiating spontaneous bacterial peritonitis from secondary peritonitis in liver cirrhosis: A retrospective multicentre study
S. Würstle[1], A. Hapfelmeier[1], F. Studen[1], A. Isaakidou[1], T. Schneider[1], R. M. Schmid[1], S. von Delius[2], F. Gundling[1, 3], R. Burgkart[1], A. Obermeier[1], U. Mayr[1], M. Ringelhan[1], S. Rasch[1], T. Lahmer[1], F. Geisler[1], C. D. Spinner[1], J. Schneider[1]
[1]Munich, [2]Rosenheim, [3]Bamberg

P 237
The transmission risk of multidrug-resistant organisms between pets and humans – Preliminary results of an exploratory case control study
C. Hackmann, P. Gastmeier, A. Genath, S. Schwarz, A. Lübke-Becker, R. Leistner
Berlin

P 238
Computationally Modeling the Human Microbiome of the Respiratory Tract
A. Dräger
Tübingen

P 239
Cancelled

P 240
Prevalence of Extended Spectrum Beta-Lactamase-producing Enterobacteriaceaeand their susceptibility to antibiotics at Nouna District Hospital
K. Dramane[1], C. Boubacar[2], S. Ali[2], D. Denise[3], S. Aurélia[4], E. Daniel[3], J. Albrecht[4]
[1]Nouna, [2]nouna, [3]hambourg, [4]Heidelberg

P 241
Laboratory-based AMR surveillance in regions of Kenya: An assessment of capacities, practices, and barriers by means of multi-facility survey
R. M. Moirongo[1], E. Lorenz[1, 2], M. Lamshöft[1, 2], J. May[1, 2], E. Daniel[2]
[1]Hamburg, [2]Braunschweig

P 242
Implementation of modern genome-based diagnostics to predict antibiotic resistance in Multi Drug Resistant-Tuberculosis (MDR-TB) or to identify pathogen variants in low- and middle-income countries
C. Gerlach[1], L. deAraujo[1], M. Vogel[2], C. Utpatel[1], V. Dreyer[1], I. Barilar[1], T. A. Kohl[1], H. Hoffmann[2], S. Niemann[1]
[1]Borstel, [2]Gauting

P 243
Pseudomonas aeruginosa self-destruction by activation and antibiotic release from lectin-targeted prodrugs
J. Meiers[1,2], K. Rox[1], A. Titz[1,2]
[1]Braunschweig, [2]Saarbrücken

P 244
Development of divalent LecA ligands as antivirulence agents against Pseudomonas aeruginosa
E. Zahorska[1,2,3], S. Kuhaudomlarp[4,5], F. Rosato[6], K. Stober[6], S. Minervini [1], S. Yousaf [1], M. Lepsik[4,7], J. Meiers[1,2,3], D. Hauck[1,2,3], E. Gillon[4], T. Kinsinger[1], K. Rox[2,3], A. K. H. Hirsch[1,2,3], W. Römer[6], A. Imberty[4], A. Titz [1,2,3]
[1]Saarbrücken, [2]Hannover, [3]Braunschweig, [4]Grenoble, [5]Bangkok, [6]Freiburg, [7]Prauge



N

O

P

R

S

SPEAKERS, CHAIRS & PRESENTING AUTHORS

T

U

V

W

X

Y

Z

Venue

Maritim Hotel Stuttgart
Seidenstr. 34 · 70174 Stuttgart
www.maritim.de

Organizing Committee

Dr. Timo Jäger, Braunschweig
Tatiana Hilger, Braunschweig

DZIF – German Center for Infection Research e.V.
Inhoffenstr. 7 - 38124 Braunschweig
Contact: presse@dzif.de

Prof. Dr. Bernd Salzberger, Vorsitzender DGI
Universitätsklinikum Regensburg
Klinik und Poliklinik für Innere Medizin I
Franz-Josef-Strauß-Allee 11, 93042 Regensburg

Congress Organization

COCS GmbH
Congress Organisation C. Schäfer
Tal 12 · 80331 Munich
Phone: 089/890677-0 · Fax: 089/890677-77
E-Mail: kongresse@cocs.de · www.cocs.de

Opening Hours Registration Desk

Wednesday, 1 June 2022	09.00 – 19.00
Thursday, 2 June 2022	08.00 – 18.00
Friday, 3 June 2022	08.00 – 13.30

Certification

Certification by the Medical Chamber is requested. All Participants will receive a general confirmation of participation and their badge by postal mail in advance before the start of the conference.

Get-together

Wednesday, 1 June 2022, 19.00, Main Hall
Classic Concert
The Academic Orchestra of the University of Tübingen

Thursday, 2 June 2022, 18.00, Main Hall
DGI/DZIF Awards
Dizzy Krisch „Vibraphone Diaries“
Vibraphone-Jazz



Registration

Please register online
www.dgi-dzif-joint-meeting.de

Participants	**250,- EUR**
Doctoral student/student*	**free entry**

*verification required

Poster Award

The four best posters will be awarded with 500,- EUR each. The presentation of awards will take place during the Get together on Thursday, 2 June 2022, from 18.00.

Cancellation policy

For written cancellation until **May 15, 2022**, a cancellation fee of 50,- EUR will be charged. After this deadline the reimbursement of the participation fee is excluded.

Abstract Book

The Abstract Book will be available online at the conference website.

Employer authorization for participation

For the purposes of the FSA codex we kindly ask for clinicians/-scientists as employed to obtain an authorization from your employer to participate in the conference if necessary. The congress is supported by pharmaceutical/medical companies. The sponsors have no influence on the scientific programme. The special sponsor symposium is clearly marked.

Photography/filming

Please be advised that filming and/or photography will be taking during the conference. The organizers will share selected pictures after the conference on the website of the organizing society. When you don't wish to be in photos or videos please notify our photographer/staff taking pictures.

Faculty/Speakers

Please note that all faculty members are obliged to disclose possible company relations at the beginning of their lecture.

All content of the scientific programme are product- and service neutral. The scientific coordination will disclose potential conflicts of interests to participants.

Sponsors

We thank our sponsors very much for their support:

Exhibitors

Altona Diagnostics GmbH, Hamburg
www.altona-diagnostics.com (Stand/Sponsor EUR 2.300,-)

bioMerieux Deutschland GmbH, Nürtingen
www.biomerieux.de (Stand EUR 1.750,-)

MSD Sharp & Dohme GmbH, Haar
www.msd.de (Stand/Sponsor/Sym EUR 21.000,-)

New England BioLabs GmbH, Frankfurt am Main
www.neb-online.de (Stand EUR 1.750,-)

Oxford Immunotec Ltd, Abingdon, Oxfordshire, UK
www.oxfordimmunotec.com/international/de (Stand EUR 1.750,-)

Sino Biological Europe GmbH, Eschborn
www.sinobiological.com (Stand EUR 1.500,-)

Status printdate: May 2022 - without engagement

Wednesday, 1 June 2022, from 19.00, Main Hall

Get-together

We look forward to inviting all participants to a get-together with the Academic Orchestra of the University of Tübingen after the sessions on Wednesday evening. At the end of the day, food and drinks will be offered and will provide a cozy setting for further discussions and networking with colleagues.

The Academic Orchestra of the University of Tübingen

The roots of the Academic Orchestra go back to the "Academic Music Association", which was founded by Friedrich Silcher, Tübingen's first university music director. Around 70 participants, mostly students from the University of Tübingen, meet weekly to rehearse and perform symphonic programs from the baroque to the modern. In recent years, the ensemble has dedicated itself to works by Bach, Beethoven, Bruckner, Mahler, Mozart, Saint-Saens, Strauss and Tchaikovsky, among others. In 2013, the violin concerto by the American composer Randall Svane was premiered seven times in Germany and the USA. Further concert tours took the musicians to Austria, France, Denmark and Italy. The orchestra is supported by members of the Stuttgart Philharmonic, who pass on their professional experience in intensive voice rehearsals.